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 1. INTRODUCTION
  
 
1. INTRODUCTION: 
1-4
 
 
Oral drug delivery has been known for decades as the most widely utilized route of 
administration among all the routes that have been explored for systemic delivery of drugs via 
pharmaceutical products of different dosage forms. Oral route is considered most natural, 
uncomplicated, convenient and safe due to its ease of administration, patient acceptance and cost 
effective manufacturing process. The reasons that the oral route achieved such popularity may be 
in part attributed to its ease of administration, belief that by oral administration of the drug is 
well absorbed. 
    All the pharmaceutical products formulated for systemic delivery via the oral route of 
administration irrespective of the mode of delivery and the design of dosage forms must be 
developed within the intrinsic characteristics of GIT physiology, pharmacokinetics and 
pharmacodynamics and formulation design to achieve a systemic approach to the successful 
development of an oral pharmaceutical dosage form. 
1.1. TABLETS: 
5
 
Tablets are solid dosage forms each containing a unit dose of one or more medicaments. 
They are intended for oral administration. Some tablets are swallowed whole or after being 
chewed, some are dissolved or dispersed in water before administration and some are retained in 
the mouth where the active ingredient is liberated. Because of their composition, method of 
manufacture or intended use, tablets present a variety of characteristics and consequently there 
are several categories of tablets.  
Tablets are usually solid, the end surfaces of which are flat or convex and the edges of 
which may be bevelled. They may exist in other shapes like triangular, rectangular, etc also. 
They may have lines or break-marks and may bear a symbol or other markings. They are 
sufficiently hard to withstand handling without crumbling or breaking. 
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Advantages of Tablets:
 6
 
 They are unit dosage form and offer the greatest capabilities of all oral dosage form 
for the greatest dose precision and the least content variability.  
 They are in general the easiest and cheapest to package and strip of all oral dosage 
forms. 
 They may provide the greatest ease of swallowing with the least tendency for 
“hang-up” above the stomach, especially when coated, provided that tablet 
disintegration is not excessively rapid. 
 They lend themselves to certain special release profile products, such as enteric or 
delayed release products. 
 They are better suited to large-scale production than the other unit oral forms. 
 They have the best-combined properties of chemical. 
 Cost is low. 
 Lighter and compact.  
 Easy to swallowing with least tendency for hang‐up.  
 Sustained release product is possible by enteric coating.  
 Objectionable odour and bitter taste can be masked by coating technique.  
 Suitable for large scale production.  
 Greatest chemical and microbial stability over all oral dosage form.  
 Product identification is easy and rapid requiring no additional steps when 
employing an embossed and or monogrammed punch face. 
 
 Disadvantages of the tablets: 
 Some drugs resist compression in to dense particles, owing to their amorphous nature or 
flocculent, low density character. 
 Drugs with poor wetting, slow dissolution properties, intermediate to large dosages, 
optimum absorption high in the GIT or any combination of these features are very 
challenging for the formulators. 
  Difficult to swallow in case of children and unconscious patients.  
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 Bitter tasted drugs, drugs with an objectionable odour or drugs that are sensitive to 
oxygen may require encapsulation or coating. In such cases, capsule may offer the best 
and lowest cost. 
 
1.1.1. Various Types of Tablets: 
7
 
  Based on the route of administration or the function, the tablets are classified as follows. 
   1) Tablets ingested orally. 
a) Compressed tablets 
b) Multiple compressed tablets 
                       І)  Layered tablets 
                      ІІ) Compression coated tablets 
c) Repeat action tablets 
d) Delayed action and enteric coated tablets 
e) Sugar and chocolate coated tablets 
f) Film coated tablets 
g) Chewable tablets 
 2) Tablets used in the oral cavity.  
a) Buccal tablets 
b) Sublingual tablets 
c) Troches and Lozenges 
d) Dental cones 
3) Tablets administered by other routes. 
a) Implantation tablets 
b) Vaginal Tablets 
4) Tablets used to prepare solution. 
a) Effervescent tablets 
b) Dispensing tablets 
c) Hypodermic tablets 
d) Tablets triturates 
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1.1.2. PHARMACEUTICAL INGREDIENTS USED IN THE FORMULATION OF 
TABLETS: 
a) Acive ingredients 
A drug substance is the Active Pharmaceutical Ingredient (API) or component that produces 
pharmacological activity. 
b) Fillers/diluents 
Diluents are used as excipients for direct compression formulas have been subjected to prior 
processing to give them flow ability and compressibility. 
Eg: Lactose, Dibasic calcium phosphate, Dextrose, Calcium carbonate, Magnesium carbonate, 
Starch, Sucrose, Mannitol. 
c) Binders 
Binders are agents which are used to impart cohesive qualities to the powdered material.    
Binders are added either dry or in liquid form during wet granulation to form granules or to 
promote cohesive compacts for directly compressed tablets. 
Eg: Povidone, Acacia, Gelatin, HPMC, Polyvinyl pyrrollidone, Hydroxypropylcellulose. 
d) Disintegrants 
Disintegrants are substances or a mixture added to a tablet formulation to facilitate its breakup 
or disintegration of the tablet after administration. The active ingredient must be released from 
the tablet matrix as efficiently as possible to allow rapid dissolution.           
Eg: Microcrystalline cellulose, Starch, Crosscarmellose sodium, Sodium starch glycolate. 
e) Lubricants 
8 
During compression lubricants acts as to reduce the interface between the face of the die and 
the surface of the tablet and act to reduce the friction at this interface during ejection of the 
tablet from the tablet press. Inadequate lubrication of this interface results in the production of 
tablets with a pitted surface and is due to their ability of the tablet surface to detach from the 
surface of the tablet die. There are two main categories of lubricants: (1) insoluble and (2) 
soluble. Insoluble lubricants are added to the final mixing stage prior to the tablet compression.
 
Eg: Magnesium stearate, Stearicacid, Glycerylpalmitostearate. 
Soluble lubricants are principally employed to overcome the possible deleterious effects of 
their insoluble counterparts on the time required for tablet disintegration and drug dissolution.  
Eg: Polyethylene glycol, Polyethylene stearate, Lauryl sulphate salt. 
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f) Glidants
 9 
Glidants are added to the formulation in order to improve the flow properties of the material to 
be fed into the die and sometimes aid in particle rearrangement within the die during the early 
stages of compression. They may act by interposing their particles between those of the other 
components and so, by virtue of their reduced adhesive tendencies, lower the overall 
interparticulate friction of the system. 
Eg: Talc, Colloidal silicon dioxide. 
g) Adsorbents 
Adsorbents are used whenever it is required to include a liquid or semisolid component, e.g. a 
drug or a flavour, within the tablet formulation.  As the production of tablets requires solid 
components, the liquid/semisolid constituent is adsorbed on to a solid component which, in 
many cases, may be one of the other components in the tablet formulation (e.g. diluent) during 
mixing. If this approach is not possible, an adsorbent is specifically included in the 
formulation.  
Eg: Magnesium oxide/Carbonate, kaolin/Bentonite. 
h) Sweetening agents/flavours 
Sweetening agents and flavours (in accordance with other dosage forms) are employed to 
control the taste and hence the acceptability of tablets. These agents are of particular 
importance if the conventional tablet contains a bitter drug or, more importantly, if the tablet is 
a chewable tablet. 
Eg: Aspartame, Sucralose, Sucrose, Glycerine, Mannitol, Sorbiltol, Acesulfame potassium. 
Flavouring agents are incorporated into the formulation to give the tablet a more pleasant 
flavouror mask an unpleasant one. Eg: Chocolate, Peppermint, Pineapple and Vanilla flavour. 
  i) Colours 
Colorants do not contribute to the therapeutic activity and to improve the product bioavailability 
or stability. Their main role is to facilitate identification and to enhance the aesthetic appearance 
of the product. All colorants used in pharmaceuticals must be approved and certified by the 
FDA. Some commonly used Pharmaceutical colorants are, 
 Eg: Erythrosine, Tartrazine, Sunset Yellow, Brilliant blue. 
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1.1.3. TABLET PROCESSING: 
6
 
Pharmaceutical products are processed all over the world using the direct compressing, 
wet granulation, or dry granulation methods. Method chosen depends on the ingredients, 
individual characteristics like flow property, compressibility etc. Right choice of method requires 
thorough investigation of each proposed ingredient in the formula for comprehensive approach 
for intractions and stability. 
  
 
 
Figure.1. Various Unit Operation Sequences In Tablet Manufacturing 
 
 
 
 
 
 
  
 Chapter 1                                                                                                                    Introduction 
 
S.B.C.P                                Department of Pharmaceutics Page 7 
 
Table No:1 Tablet manufacturing methods – advantages and Limitations 
Methods Advantages Limitations 
Direct compression 
Simple,Economical process  
No heat/moisture, good for unstable 
compounds. 
Not suitable for all API, 
generally limted to 
lowerdose compounds 
Segregation potential 
Expensive excipients. 
Wet granulation 
Aqueous 
Robust process suitable for most 
compounds. Imparts flowability to a 
formulation. Can reduce elasticity 
problems. Coating surface with 
hydrophilic polymer can improve wet- 
ability. Binds API with excipients thus 
reduce in segregation potential. 
Expensive,  
Time and energy 
consuming process. 
Specialized equipments 
required. 
Stability issues for moisture 
sensitive and thermolabile 
API with aqueous 
granulation. 
Wet granulation 
Non- aqueous 
Suitable for moisture sensitive API. 
Vacuum drying techniques can remove 
or reduce need for heat. 
 Expensive equipment. 
Need organic facility.        
Solvent recovery issues. 
Health and environment 
issues. 
Dry granulation 
Eliminates exposure to moisture and 
drying. 
Dusty procedure. 
Not suitable for all 
compounds.  
 Slow process. 
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1.1.4. MANUFACTURING DEFECTS IN TABLETS:  
During the routine production of tablets, so many defects arise with the finished tablets 
which may be due to either some faults in the formulation or in the tablet equipment and 
sometimes due to both of these reasons. Some defects are noticed immediately during 
manufacturing, but others may be noticed on storage as in the case of capping. Therefore it is 
important to perform tests at the start and during production in order to make prompt remedial 
action. The defects are: 
a) Defects during the processing of tablets are 
 Capping 
 Lamination 
 Cracking 
b) Defects due to excipients 
 Picking 
 Sticking 
 Binding 
 Chipping 
c) Defects due to other factors are 
 Mottling 
d) Defects due to machine are 
 Poor flow pattern 
 Double impression 
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1.2. COATING OF TABLETS 
 
   The application of coating is usually based on one or more of the following: 
 To mask the taste, odour or colour of the drug. 
 To provide physical and chemical protection to the drug. 
 To control the release of the drug.  
 To protect the drug from the gastric environment of the stomach with an acid           
resistant coating. 
 To incorporate another drug or formula adjuvant in the coating to avoid chemical      
incompatibility or to provide sequential drug release. 
 To provide pharmaceutical elegance by use of special colour.    
 
1.2.1. Types of coating: 
1. Sugar coating 
2. Film coating 
3. Enteric coating 
4. Extended release coating 
Layers of coating in the formulation:  
1. Tablet core 
2. Seal coating acts as an inert intermediate layer between the core and outer layer (which 
are not compatible with one another). 
3. Enteric coating acts as an outer layer which is resistant to gastric juice.  
 
1.2.2. Enteric coatings:
 10 
Enteric coatings are those which remain intact in the stomach, but will dissolve and 
release the contents once it reaches the small intestine. Their prime intension is to delay the 
release of drugs which are inactivated by the stomach contents or may cause nausea or bleeding 
by irritation of gastric mucosa. The coatings that are used now a day to produce enteric effects 
are primarily mixed acid functionality and acid ester functionality, synthetic, or modified natural 
polymers. The most extensively used polymers are Cellulose acetate, polyvinyl acetate, 
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polyhydroxy propyl methyl cellulose, Methacrylic acid copolymers. All these polymers have the 
common feature of containing the dicarboxylic, pthalic acid in partially esterified form. 
These polymers, being acid esters are insoluble in gastric media that have the pH of about 
4. And then leave the stomach and enter into the duodenum (pH 4-6) and further along the small 
intestine, where the pH is increased to a range of (pH 7-8). The primary mechanism, by which 
these polymers lose their integrity, is there by admitting the releasing drug to the intestinal fluid. 
In this ionization of the residual carboxyl groups on the chain and subsequent hydration. 
Important reasons for enteric coating are as follows: 
  * To protect acid-liable drugs from the gastric fluid. 
* To protect gastric distress or nausea due to irritation from drug. 
* To deliver drugs intended for local action in the intestines. 
* To provide a delayed release component to repeat actions. 
* Protect the drugs from harmful effect of the gastric contents; some of the drugs are     
prone to be hydrolyzed in acid media (Eg, omeprazole, pantaprazole) 
Ideal enteric coating materials should have the following properties: 
* Resistance to gastric fluids. 
* Ready susceptibility to or permeability to intestinal fluids. 
* Compatibility with most coating solution components and the drug substrates. 
* The film should not change on aging. 
* Formation of continuous film. 
* Non-toxicity. 
* Low cost. 
* Ease of application. 
1.2.3. Enteric Coating Materials:  
Enteric coatings polymers are selectively insoluble substances. They won't dissolve in the       
acidic juices of the stomach, but they will when they reach the higher pH of the small          
intestine. Most enteric coatings won't dissolve in solutions with a pH lower than 5.5.   
Commonly-used enteric coating polymers: 
  * Methacrylic acid copolymers 
    * Cellulose acetate (and its succinate and phthalate version) 
   * Polymethacrylic acid/acrylic acid copolymer 
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    * Hydroxypropyl methyl cellulose phthalate (HPMCP) 
  * Polyvinyl acetate phthalate (PVAP) 
  * Hydroxy ethyl cellulose phthalate 
  * Cellulose acetate tetra hydro phthalate 
  The earliest enteric coatings utilized formalized gelatin, this was unreliable because of 
the polymerization of gelatin could not be accurately controlled. Another was shellac, 
disadvantage was polymerization with time, and resulting in poor dissolution of the coating. The 
most extensively used polymers are CAP, PVAP. The most recently used polymers are HPMCP, 
Methacrylic acid copolymers. 
 Cellulose Acetate Phthalate (CAP) :  
Effective enteric coating, it only dissolves above pH 6 and may delay drug release longer 
than desired. It is permeable to moisture and simulated gastric fluid in comparison with 
other enteric polymers and it is susceptible to hydrolytic breakdown on storage. 
 Poly Vinyl Acetate Phthalate (PVAP) : 
      Less permeable to moisture and simulated gastric juice, it is more stable to hydrolysis on 
storage. Enteric dosage forms coated with PVAP disintegrates at pH 5. 
 Hydroxy Propyl Methyl Cellulose Pthalate (HPMCP): 
It is available in two grades HP50 and HP55. 
HP55 solutions are more viscous than HP50. 
HP50 disintegrates at pH5 and HP55 disintegrates at pH5.5. 
It has stability similar to that of PVAP and dissolves in the same pH range. The      
advantage is that it does not require Plasticizer. 
 Methacrylic acid copolymers: 11 
Two grades are available A, B and C which differs in the ratio of free carboxyl to ester 
groups therefore: 
Type A - Poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate 
chloride) has a ratio 1: 2: 0.2 and soluble in intestinal fluid from pH 6.  
Type B - Poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate 
chloride) has a ratio of 1:2:0.1 and soluble in intestinal fluid from pH 7. 
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Type C - Poly (methacrylic acid, ethyl acrylate) 1:1 and soluble in intestinal fluid from 
pH 5.5. 
 
1.3. EVALUTION OF TABLET 
Tablets formulated may undergo physical and chemical changes thereby altering the 
bioavailability of the dosage form. The tablets are to be evaluated before dispensing to maintain 
their stability and bioavailability throughout its shelf life. Evaluation of tablets can be carried as 
follows: 
a) Unofficial tests 
 Tablet appearance 
 Organoleptic properties 
 Identification markings on tablet 
 Size and shape of the tablet 
 Thickness of tablet 
 Hardness of tablet 
 Friability of tablet 
b) Official tests 
 Weight variation test 
 Content uniformity test 
 Disintegration test 
 Dissolution test. 
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1.4.  MATRIX TABLET 
12,13
 
Matrix tablets may be defined as the “oral solid dosage forms in which the drug or active 
ingredient is homogeneously dispersed throughout the hydrophilic or 
hydrophobic matrices which serves as release rate retardants”. These are the type of controlled 
drug delivery systems, which release the drug in continuous manner by both dissolution 
controlled as well as diffusion controlled mechanisms. To control the release of the drugs, which 
are having different solubility properties, the drug is dispersed in swellable hydrophilic 
substances, an insoluble matrix of rigid non swellable hydrophobic materials or plastic materials. 
ADVANTAGES OF MATRIX TABLET:  
 Can be made to release high molecular weight compounds  
 The sustained release formulations may maintain therapeutic concentrations over 
prolonged periods.  
 The use of sustain release formulations avoids the high blood concentration.  
 Sustain release formulations have the potential to improve the patient compliance.  
 Reduce the toxicity by slowing drug absorption.  
 Increase the stability by protecting the drug from hydrolysis or other derivative changes 
in gastrointestinal tract.  
 Minimize the local and systemic side effects.  
 Improvement in treatment efficacy.  
 Minimize drug accumulation with chronic dosing.  
 Usage of less total drug.  
 Improve the bioavailability of some drugs.  
 Improve of the ability to provide special effects.  
 
DISADVANTAGES OF MATRIX TABLET 
 
 The remaining matrix must be removed after the drug has been released.  
 High cost of preparation.  
 The release rates are affected by various factors such as, food and the rate transit through 
the gut.  
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 The drug release rates vary with the square root of time. Release rate continuously 
diminishes due to an increase in diffusional resistance and/or a decrease in effective area 
at the diffusion front. However, a substantial sustained effect can be produced through 
the use of very slow release rates, which in many applications are indistinguishable from 
zero-order.  
1.4.1. CLASSIFICATION OF MATRIX TABLETS:  
On the Basis of Retardant Material Used: Matrix tablets can be divided in to 5 types.  
 1. Hydrophobic Matrices (Plastic matrices) 
14
 
The concept of using hydrophobic or inert materials as matrix materials was first 
introduced in 1959. In this method of obtaining sustained release from an oral dosage form, drug 
is mixed with an inert or hydrophobic polymer and then compressed in to a tablet. Sustained 
release is produced due to the fact that the dissolving drug has diffused through a network of 
channels that exist between compacted polymer particles. Examples of materials that have been 
used as inert. or hydrophobic matrices include polyethylene, polyvinyl chloride, ethyl cellulose 
and acrylate polymers and their copolymers. The rate-controlling step in these formulations is 
liquid penetration into the matrix. The possible mechanism of release of drug in such type of 
tablets is diffusion. Such types of matrix tablets become inert in the presence of water and 
gastrointestinal fluid. 
2. Lipid Matrices
15
 
These matrices prepared by the lipid waxes and related materials. Drug release from such 
matrices occurs through both pore diffusion and erosion. Release characteristics are therefore 
more sensitive to digestive fluid composition than to totally insoluble polymer matrix. Carnauba 
wax in combination with stearyl alcohol or stearic acid has been utilized for retardant base for 
many sustained release formulation. 
3. Hydrophilic Matrices
16 
 
Hydrophilic polymer matrix systems are widely used in oral controlled drug delivery 
because of their flexibility to obtain a desirable drug release profile, cost effectiveness, and broad 
regulatory acceptance. The formulation of the drugs in gelatinous capsules or more frequently, in 
tablets, using hydrophilic polymers with high gelling capacities as base excipients is of particular 
interest in the field of controlled release. A matrix is defined as well mixed composite of one or 
more drugs with a gelling agent (hydrophilic polymer). These systems are called swellable 
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controlled release systems. The polymers used in the preparation of hydrophilic matrices are 
divided in to three broad groups,  
A. Cellulose derivatives: Methylcellulose 400 and 4000cPs, Hydroxy ethylcellulose; Hydroxy propyl 
methylcellulose (HPMC) 25, 100, 4000 and 15000cPs; and Sodium carboxymethylcellulose.  
B. Non cellulose natural or semi synthetic polymers: Agar-Agar; Carob gum; Alginates; 
Molasses; Polysaccharides of mannose and galactose, Chitosan and Modified starches.  
 
Polymers of acrylic acid: Carbopol-934, the most used variety. 
 
4. Biodegradable Matrices: 
These consist of the polymers which comprised of monomers linked to one another 
through functional groups and have unstable linkage in the backbone. They are biologically 
degraded or eroded by enzymes generated by surrounding living cells or by nonenzymetic 
process in to oligomers and monomers that can be metabolized or excreted. Examples are natural 
polymers such as proteins and polysaccharides; modified natural polymers; synthetic polymers 
such as aliphatic poly (esters) and poly anhydrides 
 5. Mineral Matrices:  
These consist of polymers which are obtained from various species of seaweeds. 
Example is Alginic acid which is a hydrophilic carbohydrate obtained from species of brown 
seaweeds (Phaephyceae) by the use of dilute alkali. 
On the Basis of Porosity of Matrix
17-20
 
 Matrix system can also be classified according to their porosity and consequently, Macro 
porous; Micro porous and Non-porous systems can be identified: 
 1. Macro porous Systems: In such systems, the diffusion of drug occurs through pores of 
matrix, which are of size range 0.1 to 1 μm. This pore size is larger than diffusant molecule size.  
2. Micro porous System: Diffusion may occurred in this type of system occurs essentially 
through pores. For micro porous systems, pore size ranges between 50 – 200 A°, which is 
slightly larger than diffusant molecules size. 
 3. Non-porous System: Non-porous systems have no pores and the molecules diffuse through 
the network meshes. In this case, only the polymeric phase exists and no pore phase is present. 
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1.4.2. POLYMERS USED IN MATRIX TABLET
21
 
 
 Hydrogels Polyhydroxyethylemethylacrylate (PHEMA), Cross-linked polyvinyl alcohol 
(PVA), Cross-linked polyvinyl pyrrolidone (PVP), Polyethylene oxide (PEO), 
Polyacrylamide (PA)  
 Soluble polymers Polyethyleneglycol (PEG), polyvinyl alcohol (PVA), 
Polyvinylpyrrolidone (PVP), Hydroxypropyl methyl cellulose (HPMC)  
 Biodegradable polymers Polylactic acid (PLA), Polyglycolic acid (PGA), 
Polycaprolactone (PCL), Polyanhydrides, Polyorthoesters 
 Non-biodegradable polymers Polyethylene vinyl acetate (PVA), Polydimethylsiloxane 
(PDS), Polyether urethane (PEU), Polyvinyl chloride (PVC), Cellulose acetate (CA), 
Ethyl cellulose (EC)  
 Mucoadhesive polymers Polycarbophil, Sodium carboxymethyl cellulose, Polyacrylic 
acid, Tragacanth, Methyl cellulose, Pectin  
 Natural gums Xanthan gum, Guar gum, Karaya gum, Locust bean gum 
 
1.4.3. EFFECT OF RELEASE LIMITING FACTOR ON DRUG RELEASE: 
22-23
 
The mechanistic analysis of controlled release of drug reveals that partition coefficient; 
diffusivity; diffusional path thickness and other system parameters play various rate determining 
roles in the controlled release of drugs from either capsules, matrix or sandwich type drug 
delivery systems. 
 A. Polymer hydration: 
It is important to study polymer hydration/swelling process for the maximum number of 
polymers and polymeric combinations. The more important step in polymer dissolution include 
absorption/adsorption of water in more accessible places, rupture of polymer-polymer linking 
with the simultaneous forming of water-polymer linking, separation of polymeric chains, 
swelling and finally dispersion of polymeric chain in dissolution medium.  
 
B. Drug solubility: 
Molecular size and water solubility of drug are important determinants in the release of 
drug from swelling and erosion controlled polymeric matrices. For drugs with reasonable 
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aqueous solubility, release of drugs occurs by dissolution in infiltrating medium and for drugs 
with poor solubility release occurs by both dissolution of drug and dissolution of drug particles 
through erosion of the matrix tablet.  
C. Solution solubility:  
In view of in-vivo (biological) sink condition maintained actively by hem perfusion, it is 
logical that all the in-vitro drug release studies should also be conducted under perfect sink 
condition. In this way a better simulation and correlation of in vitro drug release profile with in-
vivo drug administration can be achieved. It is necessary to maintain a sink condition so that the 
release of drug is controlled solely by the delivery system and is not affected or complicated by 
solubility factor. 
 D. Polymer diffusivity:  
The diffusion of small molecules in polymer structure is energy activated process in 
which the diffusant molecules moves to a successive series of equilibrium position when a 
sufficient amount of energy of activation for diffusion Ed has been acquired by the diffusant is 
dependent on length of polymer chain segment, cross linking and crystallanity of polymer. The 
release of drug may be attributed to the three factors viz, i. Polymer particle size ii. Polymer 
viscosity iii. Polymer concentration. 
i. Polymer particle size:  
Malamataris stated that when the content of hydroxyl propyl methylcellulose is higher, 
the effect of particle size is less important on the release rate of propranolol hydrochloride, the 
effect of this variable more important when the content of polymer is low. He also justified these 
results by considering that in certain areas of matrix containing low levels of hydroxyl propyl 
methylcellulose led to the burst release. 
ii. Polymer viscosity:  
With cellulose ether polymers, viscosity is used as an indication of matrix weight. 
Increasing the molecular weight or viscosity of the polymer in the matrix formulation increases 
the gel layer viscosity and thus slows drug dissolution. Also, the greater viscosity of the gel, the 
more resistant the gel is to dilution and erosion, thus controlling the drug dissolution. 
iii. Polymer concentration:  
An increase in polymer concentration causes an increase in the viscosity of gel as well as 
formulation of gel layer with a longer diffusional path. This could cause a decrease in the 
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effective diffusion coefficient of the drug and therefore reduction in drug release. The 
mechanism of drug release from matrix also changes from erosion to diffusion as the polymer 
concentration increases. 
E. Thickness of polymer diffusional path: 
The controlled release of a drug from both capsule and matrix type polymeric drug 
delivery system is essentially governed by Fick’s law of diffusion: 
JD = D dc/dx 
Where, JD is flux of diffusion across a plane surface of unit area 
 D is diffusibility of drug molecule,  
dc/dx is concentration gradient of drug molecule across a diffusion path with thickness dx. 
F. Thickness of hydrodynamic diffusion layer: 
It was observed that the drug release profile is a function of the variation in thickness of 
hydrodynamic diffusion layer on the surface of matrix type delivery devices. The magnitude of 
drug release value decreases on increasing the thickness of hydrodynamic diffusion layer δd. 
G. Drug loading dose: 
The loading dose of drug has a significant effect on resulting release kinetics along with 
drug solubility. The effect of initial drug loading of the tablets on the resulting release kinetics is 
more complex in case of poorly water soluble drugs, with increasing initial drug loading the 
relative release rate first decreases and then increases, whereas, absolute release rate 
monotonically increases. In case of freely water soluble drugs, the porosity of matrix upon drug 
depletion increases with increasing initial drug loading. This effect leads to increased absolute 
drug transfer rate. But in case of poorly water soluble drugs another phenomenon also has to be 
taken in to account. When the amount of drug present at certain position within the matrix, 
exceeds the amount of drug soluble under given conditions, the excess of drug has to be 
considered as non-dissolved and thus not available for diffusion. The solid drug remains within 
tablet, on increasing the initial drug loading of poorly water soluble drugs, the excess of drug 
remaining with in matrix increases.  
H. Surface area and volume: 
The dependence of the rate of drug release on the surface area of drug delivery device is 
well known theoretically and experimentally. Both the in-vitro and in-vivo rate of the drug 
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release, are observed to be dependent upon surface area of dosage form. Siepman et al. found 
that release from small tablet is faster than large cylindrical tablets.  
I. Diluent’s effect:  
The effect of diluent or filler depends upon the nature of diluent. Water soluble diluents 
like lactose cause marked increase in drug release rate and release mechanism is also shifted 
towards Fickian diffusion; while insoluble diluents like dicalcium phosphate reduce the Fickian 
diffusion and increase the relaxation (erosion) rate of matrix. The reason behind this is that water 
soluble filler in matrices stimulate the water penetration in to inner part of matrix, due to increase 
in hydrophilicity of the system, causing rapid diffusion of drug, leads to increased drug release 
rate.  
J. Additives:  
The effect of adding non-polymeric excipients to a polymeric matrix has been claimed to 
produce increase in release rate of hydrosoluble active principles. These increases in release rate 
would be marked if the excipients are soluble like lactose and less important if the excipients are 
insoluble like tricalcium phosphate. 
 
1.4.4. BIOLOGICAL FACTORS INFLUENCING RELEASE FROM MATRIX TABLET 
 
 Biological half-life.  
 Absorption.  
 Metabolism  
 Distribution  
 Protein binding  
 Margin of safety  
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1.5. COLON TARGETED DRUG DELIVERY SYSTEM 
 
 Colon Targeted Drug Delivery System (CTDDS) may be following the concept of 
Controlled or Sustained drug Delivery System. For CTDDS oral route of administration has 
received most attention. Local delivery allows topical treatment of inflammatory bowel disease. 
Colon is highly desirable for local treatment of a variety of bowel diseases such as ulcerative 
colitis, Crohn’s disease, colonic cancer, local treatment of colonic pathologies and systemic 
delivery of protein and peptide drugs.
24-25
 
For effective and safe therapy of these colonic disorders, colon specific drug delivery is 
necessary i.e. drug release and absorption should not occur in the stomach as well as the small 
intestine, and neither the bioactive agent should be degraded in either of the dissolution sites but 
only released and absorbed once the system reaches the colon
26
. Today, colon specific drug 
delivery is challenging task to pharmaceutical technologist. The colon is believed to be a suitable 
absorption site for peptides and protein drugs for the following reasons,  
 
i. Less diversity,  
ii. Intensity of digestive enzymes, 
 
Comparative proteolytic activity of colon mucosa is much less than that observed in the 
small intestine, thus CTDDS protects peptide drugs from hydrolysis, and enzymatic degradation 
in duodenum and jejunum, and eventually releases the drug into ileum or colon which leads to 
greater systemic bioavailability
27
. The concentration of drug reaching the colon depends on 
formulation factors, the extent of retrograde spreading and the retention time
28
. Coating of the 
drugs with pH-sensitive polymers provides simple approach for colon-specific drug delivery 
29
. 
 
 The bioactive agent should be degraded in either of the dissolution sites but only released 
and absorbed once the reaches the colon. Because the colon has a long residence time 72 hours 
and high water content it favors absorption of poorly absorbed drug molecule may have an 
improved bioavailability, CTDDS has been employ to achieve following objectives, 
i) Sustained delivery to reduce dosing frequency 
ii) Delay delivery of drug to achieve high concentration in treatment of disease of distal 
gut 
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iii) To delay deliver to a time appropriate to treat acute phase of disease  
iv) Deliver drug to that region that is less hostile metabolically, drug which is acid and 
enzyme labile such as proteins
30
. 
 Benefits of Colon Target Drug Delivery System
31-32
 
a) Reducing the adverse effects in the treatment of colonic diseases (ulcerative colitis, 
colorectal cancer, Crohn’s disease etc.)  
b)  Minimizing extensive first pass metabolism of steroids.  
c) High retention time thus increasing the bioavailability of poorly absorbable drugs.  
d)  Increased patient compliance.  
e) Colon is an ideal site for the delivery of agents to cure the local diseases of the colon.  
f) Decreases the side effects in the treatment of colon diseases.  
g) Prevents gastric irritation resulting due to the administration of NSAIDs.  
h) Minimizes first pass metabolism.  
i) Provides suitable environment for proteins and peptides that are sensitive to gastric fluid 
and digestive enzymes.  
j)  Decreased frequency of administration. Hence decreased cost of drugs.  
k)  High retention time thus increasing the bioavailability of poorly absorbable drugs.  
l) Targeted drug delivery to the colon in treatment of colonic disease ensures direct 
treatment at the affected area with lower dose and less systemic side effects. 
m)  The colonic drug delivery can also be utilized as the threshold entry of the drugs into 
blood for proteins and peptides which degraded or poorly absorbed in upper GIT.  
n) The colon targeted drug delivery can also be used for chronotherapy for effective 
treatment of diseases like asthma and angina.  
o)   High retention time thus increasing the bioavailability of poorly absorbable drugs. 
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Limitations of colon target Drug Delivery System
31, 33 
 
a) Successful delivery requires the drug to be in solution before it arrives in the colon, but 
the fluid content in the colon is lower and more viscous than in upper GIT, which is the 
limiting factor for poorly soluble drugs.  
b) Lower surface area and relative tightness of the tight junctions in the colon can restrict 
drug transport across the mucosa in to the systemic circulation. 
c) There are variations among individuals with respect to the pH level in the small intestine 
and colon which may allow drug release at undesired CSDDS site. 
d) The pH level in the small intestine and caecum are similar which reduces site specificity 
of formulation. 
e)  The major disadvantage of colonic delivery of drug is poor site specificity.  
f)  Diet and diseases can affect colonic micro flora which can negatively affect drug 
targeting to colon. 
g)   Nature of food present in GIT can affect drug pharmacokinetics.  
h) Enzymatic degradation may be excessively slow which can cause interruption in polymer 
degradation and thus alters the release profile of drugs.  
 
Need for colon targeting drug delivery: 
34, 35, 36, 37
  
 
 Targeted drug delivery to the colon to ensure that direct treatment at the disease site 
(local delivery), at lower dosing and fewer systemic side effects.
 
 
 Site-specific or targeted drug delivery system would allow oral administration of peptide 
and protein drugs, colon-specific formulation could also be used to prolong the drug 
delivery.  
 Colon-specific drug delivery system is considered to be beneficial in the treatment of 
colon diseases.  
 The colon is a site where both local or systemic drug delivery could be achieved, topical 
treatment of inflammatory bowel disease, e.g. ulcerative colitis or Crohn’s disease. Such 
inflammatory conditions are usually treated with glucocorticoids and sulphasalazine .  
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 A number of others serious diseases of the colon, e.g. colorectal cancer, might also be 
capable of being treated more effectively if drugs were targeted to the colon .  
  Formulations for colonic delivery are also suitable for delivery of drugs which are polar 
and/or susceptible to chemical and enzymatic degradation in the upper GI tract, highly 
affected by hepatic metabolism, in particular, therapeutic proteins and peptides.  
 
1.5.1. ANATOMY AND PHYSIOLOGY OF COLON 
38 
 
 
In GIT, large intestine starts from the ileocecal junction to the anus having a length of 
about 1.5m (adults) and is divided into three parts, viz. colon, rectum and anal canal. The colon 
consists of caecum, ascending colon, transverse colon, descending colon and sigmoid colon. 
Colon is made up of four layers, serosa, muscularis externa, submucosa and mucosa. The 
epithelium consists of a single layer of cells, which lines the crypts and covers the surface of the 
mucosa. Three major cell types found in the epithelium are the columnar absorptive cells, goblet 
(mucous) cells and entero endocrine cells. Adjacent columnar absorptive cells are attached to one 
another near apical margins by a junctional complex.  
                               
Mucus production in the colon is a function of goblet cells and the proportion of goblet 
cells increases in the elderly. The colon and the rectum have an anatomic blood supply. The 
arterial blood supply to the proximal colon is from the superior mesenteric artery and the inferior 
mesenteric artery supplies the distal colon. The venous drainage is via the superior (proximal 
colon) and inferior (distal colon) veins. The arterioles and capillary branches pass to the 
epithelial surface between the crypts and form an extensive network of capillary plexi. The 
mucus lining of GIT forms a barrier against bacterial invasion of the gut wall.  
 Chapter 1                                                                                                                    Introduction 
 
S.B.C.P                                Department of Pharmaceutics Page 24 
 
 
Figure: 2 Anatomy of Colon. 
 
1.5.2. COLONIC MICRO FLORA 
39
 
The sluggish movement of material through the colon allows a large microbial population 
to succeed there. Over 400species of bacteria found, for the most part anaerobes and a small 
number of fungi. The bacterial count (colony forming unit/mL, CFU/mL) is 1011-1012CFU/mL 
in colon. Most of them are anaerobes. E.g.: Bacteroides, Bificlobacterium, Eubacterium, 
Peptococcus, Peptostreptococcus, Ruminococcus and Clostridium; others are facultative 
anaerobes e.g.: E.Coli. Among all of them 20-30% are Bacteroides. 
 
1.5.3. pH IN THE COLON  
Radio telemetry has been used to measure the gastrointestinal pH in healthy human 
subjects. The average pH of the caecum and colon lumen is 6.8 – 7.0. The highest pH levels   
(7.5 – 8.0) were found in the terminal ileum. On entry into the colon, the pH dropped to 6.4 –7.0. 
The pH in the mid-colon was measured at 6.6 – 7.4 and in the left colon, 7.0 – 7.7. The fall in pH 
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on entry into the colon is due to the presence of short chain fatty acids arising from the bacterial 
fermentation of polysaccharides. Colonic pH has been shown to be reduced in disease. 
 
1.5.4. FUNCTIONS OF THE COLON 
The major function is the consolidation of the intestinal contents into feaces by the 
absorption of water and electrolytes. The absorptive capacity is very high. In healthy human 
colon, sodium and chloride ions are usually absorbed and potassium and bicarbonate ions are 
usually secreted. Activity in the colon can be divided into segmenting and propulsive 
movements. Segmenting movements caused by circular muscle and causing the appearance of 
the sac-like haustra, predominate and resulting in mixing of the luminal contents. Significant 
propulsive activity, associated with defecation and affected by longitudinal muscle, is less 
common and occurs an average of three or four times daily. 
 
1.5.5. BARRIERS TO COLONIC DRUG ABSORPTION
38
 
Drug absorption through the colon can be limited by number of barriers. In the lumen 
itself, specific and non-specific drug binding can occur through the interaction of drug with 
dietary components and products released from bacteria residing in the colon. The mucus barrier 
at the epithelial surface can present a formidable physical barrier to uptake as a result of specific 
and non-specific drug binding. Mucus-drug incompatibility can be compounded if the delivered 
drug stimulates the mucus secreting goblet cells because the transit through mucus is diffusion 
limited, the greater the thickness of this barrier, longer the time required for an individual 
molecule to reach the epithelial surface. 
The unstirred water layer (the space between mucus layer and epithelial cells) presents 
another barrier to colonic absorption, particularly for lipophilic drugs. A pH gradient may also 
exist across the unstirred water layer. This lower pH at the colonocyte surface may dramatically 
alter drug solubility and since drug transport within the unstirred layer is driven by chemical 
potential, altered drug solubility can affect absorption. Probably the most significant barrier to 
epithelial transport of drugs in the colon occurs at the level of the epithelium. Here, the lipid 
bilayers of the individual colonocytes and the occluding junctional complex (OJC) between these 
cells provide a physical barrier to drug absorption. 
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1.5.6. FACTORS AFFECTING COLONIC DRUG DELIVERY 
 
There are many factors that influence the drug delivery to colon. They include 
 
1. Transit through GIT 
In order to reach colon in an intact form, the drug delivery systems should surpass the 
barriers in the stomach and small intestine. Normally, the small intestinal transit is not influenced 
by the physical state, size of the dosage form and presence of food in the stomach. The mean 
transit time of the dosage form is about 3-4 hours to reach the ileocecal junction. During this 
period the dosage form is exposed to enzymes present in small intestine. Compared to the other 
region of GIT, movement of material through the colon is slow. The colonic transit time of a 
capsule in adult is 20-35 hrs. Improved residence time with subsequent longer transit time and 
the contact of dosage form with microflora in colon govern the release and absorption of drug 
from dosage form. 
2. Gastric emptying 
Once the dosage form enters the stomach, the primary concern is how long it will remain 
there before being discharged into the duodenum. Emptying generally completes in 5-10 min up 
to 2 hours depending on phase of the stomach at the time of drug administration. It is preferable 
for a colonic delivery system to spend little time in the stomach. Such system may release the 
drug at a distant locus from the colon. 
3. Stomach and intestinal pH 
The pH of GIT must be considered when enteric coatings (bioerodiblepolymers) are used 
to deliver drugs to colon. Since, in such systems, GIT pH gradient is used to trigger drug release. 
4. Colonic microflora 
Microflora of the colon has a number of implications in health and the treatment of 
diseases such as IBD. The concentration of gut microflora rises considerably in the terminal 
ileum to reach extraordinarily high levels in the colon. The gut bacteria are capable of catalysing 
a wide range of metabolic events. Many colon-specific drug delivery systems rely on enzymes 
unique to gut microflora to release active agents in the colon. However, only two or three 
enzyme systems namely azoreductases and glycosidases (including glucuronidase) have been 
explored in this area. A large number of polysaccharides are actively hydrolysed by gut 
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microflora leading to the possibility of using naturally occurring biopolymer as drug carriers. 
The second class of enzymes used to trigger the release of drugs in the colon is glycosidases 
(including glucuronidases). The main bacterial groups responsible for β- glycosidases activity are 
lactobacilli, bacteroides and bifidobacteria. 
5. Gastrointestinal Disease State 
Gastrointestinal diseases such as IBD (inflammatory bowel disease), crohn's disease, 
constipation, diarrhoea and gastroenteritis may affect the release and absorption of drug from 
colon-specific drug delivery system. 
 
1.5.7. COLONIC ABSORPTION 
 
As absorption capacity of colon is very high which is attributed to the colon transit time, 
which can be as long as 20-35 hours, hence it is ideally suited for absorption. The absorption is 
influenced by the transport of water, electrolytes and ammonia across the mucus and it is more in 
the proximal colon than the distal colon. Drug molecules pass from the apical to basolateral 
surface of epithelial cells by 
 
 
                  Figure: 3 Drug release pattern of coated system at different pH conditions in GIT 
 Passing through colonocytes (trans cellular transport), or 
 Passing between adjacent colonocytes (para cellular transport) 
 
Small amphipathic drugs may pass this barrier through transcellular transport. 
Paracellular transport may be the most promising means of general drug absorption in colon. 
Additionally, carrier mediated uptake of the drug in the colon is not extensive and usually related 
to the metabolic events of the resident bacteria. Receptor mediated endocytosis and pinocytosis 
could, however lead to transcellular transport of drug. 
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1.6. INFLAMMATORY BOWEL DISEASE
40
 
 
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon 
and small intestine. Crohn's disease and ulcerative colitis are the principal types of inflammatory 
bowel disease. It is important to note that not only does Crohn's disease affect the small intestine 
and large intestine, it can also affect the mouth, esophagus, stomach and the anus whereas 
ulcerative colitis primarily affects the colon and the rectum. 
  
 1.6.1. Ulcerative colitis
41
 
  Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, 
which starts in the rectum and generally extends proximally in a continuous manner through part 
of or the entire colon however, some patients with proctitis or left-sided colitis might have a 
caecal patch of inflammation. Bloody diarrhoea is the characteristic symptom of the disease. 
Ulcerative colitis is a nonspecific inflammatory bowel disease of unknown etiology that 
effects the mucosa of the colon and rectum. The treatment of ulcerative colitis depends on the 
amount of the large bowel affected and the severity of the inflammation. If the disease is 
confined only to the lower part of the bowel, a mild attack may be treated with drugs (such as 
mesalazine or steroids) given directly into the rectum through the back passage (e.g.by an enema 
or suppositories). Ulcerative colitis is a chronic, or long lasting, disease that causes inflammation 
irritation or swelling and sores called ulcers on the inner lining of the large intestine. Ulcerative 
colitis most often begins gradually and can become worse over time. Symptoms can be mild to 
severe. Most people have periods of remission times when symptoms disappear that can last for 
weeks or years. The goal of care is to keep people in remission long term. 
 
Figure: 4 Diagram of Inflamed and normal colon 
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1.6.2. Signs and symptoms of Ulcerative colitis  
The most common signs and symptoms of ulcerative colitis are diarrhea with blood or 
pus and abdominal discomfort. Other signs and symptoms include  
 An urgent need to have a bowel movement  
 Nausea or loss of appetite  
 Weight loss  
 Fever  
 Anemia is a condition in which the body has fewer red blood cells than normal  
Less common symptoms include  
 Joint pain or soreness  
 Eye irritation  
 Certain rashes  
The symptoms a person experiences can vary depending on the severity of the inflammation and 
where it occurs in the intestine. When symptoms first appear,  
 Most people with ulcerative colitis have mild to moderate symptoms  
 About 10 percent of people can have severe symptoms, such as frequent, bloody 
bowel movements, fever and severe abdominal cramping 
 
 
Figure: 5 Diagram of ulcerative colitis 
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1.6.3. CAUSES OF ULCERATIVE COLITIS
42
 
The exact cause of ulcerative colitis is unknown. Researchers believe the following 
factors may play a role in causing ulcerative colitis:  
 Overactive intestinal immune system  
 Genes  
 Environment  
Overactive intestinal immune system.  
Scientists believe one cause of ulcerative colitis may be an abnormal immune reaction in 
the intestine. Normally, the immune system protects the body from infection by identifying and 
destroying bacteria, viruses, and other potentially harmful foreign substances. Researchers 
believe bacteria or viruses can mistakenly trigger the immune system to attack the inner lining of 
the large intestine. This immune system response causes the inflammation, leading to symptoms.  
Genes.  
Ulcerative colitis sometimes runs in families. Research studies have shown that certain 
abnormal genes may appear in people with ulcerative colitis. However, researchers have not 
been able to show a clear link between the abnormal genes and ulcerative colitis. 
Environment. 
Some studies suggest that certain things in the environment may increase the chance of a 
person getting ulcerative colitis, although the overall chance is low. Nonsteroidal anti-
inflammatory drugs, antibiotics, and oral contraceptives may slightly increase the chance of 
developing ulcerative colitis. A high-fat diet may also slightly increase the chance of getting 
ulcerative colitis. 
Some people believe eating certain foods, stress, or emotional distress can cause 
ulcerative colitis. Emotional distress does not seem to cause ulcerative colitis. A few studies 
suggest that stress may increase a person’s chance of having a flare-up of ulcerative colitis. Also, 
some people may find that certain foods can trigger or worsen symptoms. 
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1.6.4. INCIDENCE AND PREVALENCE OF ULCERATIVE COLITIS 
Ulcerative colitis occurs worldwide. It is considered common in most of Europe and 
North America and uncommon in most of the developing Asian countries. The 
incidence/prevalence of ulcerative colitis varies not only according to geographical region but 
also with race and ethnicity.  
How is ulcerative colitis diagnosed?  
A health care provider diagnoses ulcerative colitis with the following:  
 Medical and family history  
 Physical exam  
 Lab tests  
 Endoscopies of the large intestine  
Medical and Family History  
Taking a medical and family history can help the health care provider diagnose ulcerative 
colitis and understand a patient’s symptoms. The health care provider will also ask the patient 
about current and past medical conditions and medications.  
Physical Exam  
A physical exam may help diagnose ulcerative colitis. During a physical exam, the health 
care provider most often  
 checks for abdominal distension, or swelling  
 listens to sounds within the abdomen using a stethoscope  
 taps on the abdomen to check for tenderness and pain 
Lab Tests  
A health care provider may order lab tests to help diagnose ulcerative colitis, including blood and 
stool tests.  
Blood tests  
A blood test involves drawing blood at a health care provider’s office or a lab. A lab technologist 
will analyze the blood sample. A health care provider may use blood tests to look for  
 Anemia  
 Inflammation or infection somewhere in the body  
 Markers that show ongoing inflammation  
 Low albumin, or protein common in patients with severe ulcerative colitis  
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Stool tests.  
A stool test is the analysis of a sample of stool. A health care provider will give the 
patient a container for catching and storing the stool at home. The patient returns the sample to 
the health care provider or to a lab. A lab technologist will analyze the stool sample. Health care 
providers commonly order stool tests to rule out other causes of GI diseases, such as infection.  
 
Endoscopies of the Large Intestine  
Endoscopies of the large intestine are the most accurate methods for diagnosing 
ulcerative colitis and ruling out other possible conditions, such as Crohn’s disease, diverticular 
disease, or cancer. Endoscopies of the large intestine include  
 Colonoscopy  
 Flexible sigmoidoscopy  
 
Colonoscopy 
Colonoscopy is a test that uses a long, flexible, narrow tube with a light and tiny camera 
on one end, called a colonoscope or scope, to look inside the rectum and entire colon. In most 
cases, light anesthesia and pain medication help patients relax for the test. The medical staff will 
monitor a patient’s vital signs and try to make him or her as comfortable as possible. A nurse or 
technician places an intravenous (IV) needle in a vein in the patient’s arm or hand to give 
anesthesia. For the test, the patient will lie on a table or stretcher while the gastroenterologist 
inserts a colonoscope into the patient’s anus and slowly guides it through the rectum and into the 
colon. The scope inflates the large intestine with air to give the gastroenterologist a better view. 
The camera sends a video image of the intestinal lining to a monitor, allowing the 
gastroenterologist to carefully examine the tissues lining the colon and rectum. The 
gastroenterologist may move the patient several times and adjust the scope for better viewing. 
Once the scope has reached the opening to the small intestine, the gastroenterologist slowly 
withdraws it and examines the lining of the colon and rectum again.  
A colonoscopy can show irritated and swollen tissue, ulcers, and abnormal growths such 
as polyps extra pieces of tissue that grow on the inner lining of the intestine. If the 
gastroenterologist suspects ulcerative colitis, he or she will biopsy the patient’s colon and 
rectum. A biopsy is a procedure that involves taking small pieces of tissue for examination with 
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a microscope. A health care provider will give patients written bowel prep instructions to follow 
at home before the test. The health care provider will also give patients information about how to 
care for themselves following the procedure. 
 
Flexible sigmoidoscopy.  
Flexible sigmoidoscopy is a test that uses a flexible, narrow tube with a light and tiny 
camera on one end, called a sigmoidoscope or scope, to look inside the rectum, the sigmoid 
colon, and sometimes the descending colon. In most cases, a patient does not need anesthesia.  
For the test, the patient will lie on a table or stretcher while the health care provider inserts the 
sigmoidoscope into the patient’s anus and slowly guides it through the rectum, the sigmoid colon 
and sometimes the descending colon.  
The scope inflates the large intestine with air to give the health care provider a better 
view. The camera sends a video image of the intestinal lining to a monitor, allowing the health 
care provider to examine the tissues lining the sigmoid colon and rectum. The health care 
provider may ask the patient to move several times and adjust the scope for better viewing. Once 
the scope reaches the end of the sigmoid colon, the health care provider slowly withdraws it 
while examining the lining of the colon and rectum again. The health care provider will look for 
signs of bowel diseases and conditions such as irritated and swollen tissue, ulcers, and polyps. 
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Figure: 6 Types of ulcerative colitis 
 
 
 Proctitis – Involves only the rectum 
 Proctosigmoiditis – Involves the rectum and sigmoid colon (the lower segment of the 
colon before the rectum) 
 Distal colitis –Involve only the left side of the colon 
 Pancolitis –Involves the entire colon 
 Backwash ileitis – Involves the distal ileum 
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1.6.5. Pathophysiology of ulcerative colitis 
43
 
 
 
Figure: 7 Pathophysiology of ulcerative colitis 
1. Antibodies and B cells 
The pathophysiology of UC is shown in Fig. 7. An increase of lymphocytes, especially 
activated T cells and IgG-containing B cells, is seen in the colonic mucosa. This may induce the 
increased production of antibodies directed against intestinal antigens and auto antigens. In 
addition, a role of the type I allergic response has been suggested in the development of acute 
exacerbation. Auto antibodies, such as anti colon antibody and anti-neutrophil cytoplasmic 
antibody (ANCA), are detected in the serum of some UC patients and damage to the colonic 
mucosa is assumed to be due to antibody dependent cell-mediated cytotoxicity (ADCC) 
involving these auto antibodies. In other words, a functional abnormality of mucosal T cells and 
associated activation of antibody-producing cells seems to promote the local production of auto 
antibodies in the colonic mucosa that may contribute to the pathogenesis of this disease. 
However, these antibodies are not present in all patients and there is no correlation between such 
antibodies and disease activity or the duration of illness. Thus, it is possible that these antibodies 
may develop secondary to inflammation without any pathogenic activity. At the present time, 
therefore, there is not enough evidence about the role of autoimmunity in UC. 
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2. Cytokines and T cells 
In the normal state, the mucosal immune system is involved in the suppression or 
inhibition of immune responses to the intestinal contents. The concept that this tightly regulated 
state is altered in UC has been proposed by many groups. Various abnormalities of the cytokine 
network occur in the colonic mucosa of UC patients, resulting in uncontrolled and sustained 
inflammation. We have focused on defective regulation of the differentiation and proliferation of 
the thymic T cell lineage in UC patients and have described a factor that affects the processing of 
thymic T cells. Purification of this factor revealed that it was IL-7. Because IL-7 produced by 
intestinal epithelial cells regulates the proliferation of mucosal T cells, disruption of this 
mechanism could lead to abnormal perpetuation of inflammation. There is considerable evidence 
that defective mucosal immunoregulation, including abnormal changes of T cells, B cells, 
granulocytes, mac-rophages, and the cytokines and chemokines produced by these cells, plays a 
major role in the pathogenesis of UC. The current need is to clarify the factors that lead to 
defective immunoregulation. 
 
 
 
                                                 Figure: 8 Microscopical structure of ulcerative colitis 
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2. AIM AND PLAN OF WORK 
 
2.1 AIM OF WORK 
 
The aim of present study was to formulate the colon targeted matrix tablet of Ibuprofen and to 
evaluate the formulation for various parameter to release the active ingredient after predetermine time in 
a predetermine location with better pharmaceutical and therapeutic properties.  
 Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic 
properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIA, 
which are thought to act through inhibition of prostaglandin synthesis. The half-life of Ibuprofen 
is 2-4 hours. It is used in the management of many inflammatory conditions. 
 The increasing incidence of ulcerative colitis has been reported from western countries and other 
parts of the world. Even in India this disease is diagnosed to be more common. Though, there is 
need to study the disease and its complications from our country. Inflammatory bowel disease is 
an uncommon but important health problem. It is particularly likely to affect young people. The 
present investigation deals with development of effective and stable enteric coated matrix tablet 
of Ibuprofen for the effective treatment of inflammatory bowel diseases. 
 
 To formulate Ibuprofen matrix tablets and coated with enteric polymer. 
 To evaluate the formulated tablets as per requirements of IHS standards. 
 To evaluate the most satisfactory formulation. 
 To select the best formulation based on in-vitro studies for colon targeting. 
 To perform stability studies on the most satisfactory formulation. 
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2.2 PLAN OF WORK 
The present work was carried out to formulate the colon targeted matrix tablets of 
Ibuprofen and to evaluate the various parameters. It was planned to carry out this work as 
outlined below. 
 To carry out the Preformulation studies to maximize the chances in formulating an 
acceptable, safe, efficacious and stable product. 
a) Evaluation of API 
 Description 
 Solubility 
 Melting point 
 Particle size distribution 
   Loss on drying 
                                      b) Drug excipient compatibility studies 
 Physical observation 
 FT-IR studies. 
 Formulation of uncoated Ibuprofen tablets by direct compression method. 
 Evaluation of the granules such as 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’s ratio 
 Evaluation of physical parameters for compressed tablets. 
 Weight variation 
 Thickness 
 Hardness 
 Friability 
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 Disintegration 
 Determination of drug content 
 Coating of the formulated Ibuprofen tablets by using Eudragit FS 30D by pan coating 
method. 
 Evaluation of the coated tablet. 
 Evaluation of the most satisfactory formulation. 
 In-vitro Drug Release Studies. 
 To carry out the stability studies for the best formulation. 
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3. REVIEW OF LITERATURE 
 
Neha Singh Raghuvanshi et al., (2014)
44
 Formulated and evaluated matrix tablets of 
Prednisolone  by wet granulation method using various proportions of Sterculia gum with 
Carbopol 934P and Sterculia gum with Ethyl cellulose at 1:1, 1:5 and 1:2 ratio. Coating was 
carried out by using 1:1 ratio of Eudragit L100 and Eudragit S100. All the preparation were 
evaluated for Pre compressional properties, Post compressional properties and in-vitro 
dissolution study in different pH buffer of 0.1N HCL , pH 7.4 and pH 6.8 in order to mimic GIT 
condition. All the parameters were found to be within the limits. Formulation F4 showed 85.46% 
at the end of 12 hrs and emerged as best formulation. 
 
Sumit Kumar et al., (2012)
45
 Developed colon targeted matrix tablets of Naproxen to prolong 
the release for sustained effect. Different formulation (MT1 TO MT3) batches were made with 
the help of different polymers and their different proportions (Guar Gum, Xanthan Gum) with 
the help of Wet granulation techniques. The prepared matrix tablets were evaluated in terms of 
their pre-compression parameters, physical characteristics like hardness, friability, uniformity of 
weight, uniformity of drug content and in-vitro drug release. All the parameters were found to be 
within the limits. From this study it concluded that the batch MT3 showed 77.99 % drug release 
then the other batches. The batch MT3 showed maximum prolonged release up to 12 hrs and 
concluded as best formulation. 
 
Biresh Kumar Sarkar et al., (2012)
46
 Developed colon targeted matrix tablets of Flurbiprofen 
to prolonged the release for sustained effect. Different formulation (F1 TO F9) batches were 
made with the help of different polymers and their different proportions (Guar Gum, Eudragit 
RL, Eudragit RS) with the help of Wet granulation techniques. The prepared matrix tablets were 
evaluated in terms of their pre-compression parameters, physical characteristics like hardness, 
friability, uniformity of weight, uniformity of drug content and in-vitro drug release. All the 
parameters were found to be within the limits. The batch F7 showed the maximum prolonged  
drug release 99.6%  up to 12 hrs and concluded that the batch F7 as best formulation. 
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Sharma Madhu et  al., (2012)
47 
 Formulated and evaluated the sustained delayed release tablets 
of Mesalazine. The time and pH dependent drug delivery system, reduce the frequency of dose 
administeration, to prevent ulcerative colitis by developing sustained delayed release tablets of 
Mesalazine using combination of Eudragit S-100 and L-100 as enteric coating. The core tablets 
of Mesalazine were prepared using wet granulation containing a superdisintegrant. The aim of 
study was to develop colon specific drug delivery of Mesalazine sustained release matrix tablets 
for ulcerative colitis using HPMC K-4M and HPMC K-15M as a semisynthetic polymer. Effect 
of polymer concentration and superdisintegrant level was also investigated. The matrix tablets of 
Mesalazine are subjected to an in-vitro drug release study using simulated gastric fluid (0.1N 
HCl) for 2 hours, simulated intestinal fluid (pH 7.4) for 3 hours and simulated colonic fluid (pH 
6.8) for 7 hours as dissolution fluid. The study showed that, lag time prior to drug release was 
highly affected by the coating. Colon drug delivery is advantageous in treatment of colonic 
disease and oral delivery of drugs that are unstable and susceptible to enzymatic degradation in 
upper GI tract. The disintegration data obtained from tablets demonstrated that disintegration 
data rate of studied tablets is dependent on: (i) The polymer used to coat the tablets (ii) pH of 
disintegration media. Results also demonstrated that combination of Eudragit S-100 and L-100 
can be successfully used to coat tablets for colon targeted delivery of drug. Tablets were 
evaluated in terms of their pre-compression parameters, physical characteristics like hardness, 
friability, uniformity of weight, uniformity of drug content and in-vitro drug release. All the 
parameters were found to be within the limits. Formulation F4 showed 90.25% at the end of 12 
hrs and emerged as best formulation. 
 
R.Prashanthi et al., (2014)
48
 Developed the controlled release matrix tablets of Flurbiprofen by 
selecting different polymers like HPMC K100, Sodium Carboxy Methyl Cellulose, Xanthan gum 
and Guar gum. All the formulations were prepared by direct compression method using 12mm 
punch on 8 station rotary tablet punching machine. The blend of all the formulations showed 
good flow properties such as angle of repose, bulk density, tapped density. The prepared tablets 
were showed good post compression parameters and they passed all the quality control 
evaluation parameters as per I.P limits. Among all the formulations F12 formulation that is with 
Guar Gum showed maximum percentage drug release 99.18 % in 12 hours. Hence it is 
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considered as optimized formulation. The retardation in the release of the drug from optimized 
formulation is may be due to the increase in the concentration of the polymer.  
 
Lone Krishnakumar Devrao et al., (2012)
49
 Formulated and Evaluated the Matrix Tablet of 
Mesalazine with Hydroxypropylmethylcellulose Phthalate. In this study slow released matrix 
tablets of Mesalazine were prepared using pH sensitive polymer HPMC-P with six 
concentrations by wet granulation method. The granules were evaluated for angle of repose, bulk 
density, tapped density, compressibility index and Hausners ratio. The tablets were subjected to 
weight variation, hardness, friability and drug content test. Invitro release studies revealed that 
only one formulation, P3 qualified the first stage of release while all the formulations qualified 
the second stage of drug release except P4 which deviated slightly. The release profiles were 
affected by variable concentration of matrix forming polymer and hence, the release of 
Mesalazine retarded with increase in proportion of HPMC-P. As HPMC-P is a pH sensitive 
polymer with threshold value 5.8 because of this effectively prevented the escape of drug at acid 
stage but allowed considerable amounts to be released in buffer stage I. The prepared tablets 
were evaluated in terms of their pre-compression parameters, physical characteristics like 
hardness, friability, uniformity of weight, uniformity of drug content and in-vitro drug release. 
All the parameters were found to be within the limits. Formulation P6 showed 99.32% at the end 
of 12 hrs and emerged as best formulation. 
 
Rajeswari P. et al., (2016)
50  
Developed colon targeted drug delivery system by using Chitosan 
as a carrier for Mesalamine. Matrix tablets containing various excipients and Chitosan were 
prepared by wet granulation technique using different binder systems. The prepared  tablets were 
evaluated for Hardness, Weight variation, Drug uniformity, Friability and In-vitro Drug release 
study. All the parameters were found to be within the limits. The final product is expected to 
have the advantage of being biodegradable and pH dependant. The matrix tablet containing 
Chitosan as a carrier and xanthum gum as binder was found to be suitable for targeting 
mesalamine for local action in the colon as compare to other matrix tablets containing different 
binders. Matrix tablets containing Chitosan released 99.99% of mesalamine in simulated colonic 
fluid. The stability study for prepared tablets at 40ᵒC/75% relative humidity for three months 
showed no significant change in In-vitro drug release pattern. The results of in-vitro study 
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indicate that matrix tablets containing Chitosan as carrier and xanthum gum as binder are most 
suitable to deliver the drug specifically in colonic region. The final formulation of mesalamine 
for colon-specific drug delivery gives pH, time and enzyme controlled release. Formulation F6 
showed 99.29% at the end of 24 hrs and emerged as best formulation. 
 
Prasanta kumar choudhury et al., (2012)
51
  Developed the matrix tablets of Ornidazole were 
prepared by wet granulation method using matrix forming natural polymers like Guar gum and 
Xanthan gum in combination with different proportions. The further effect of enteric coat on the 
matrix tablets for colon specific drug release was investigated. The Ornidazole optimized matrix 
formulation OM1 showed drug release around 32.37±0.33% in 2 hrs. So it was further enteric 
coated with 5% Eudragit S100 and coded as OME1 which showed 44.09±0.16% of drug release 
after 12 hrs. All formulations were subjected to Hardness test, Friability test, determination of 
uniform diameter and thickness, drug content for optimization and further evaluation. In-vitro 
dissolution studies indicated that the drug release in upper part of GIT from matrix tablets of 
Ornidazole can be prevented by enteric coating with pH sensitive polymer (Eudragit®S100), 
which releases the drug specifically in colonic region to achieve target delivery. All the 
parameters were found to be within the limits. Formulation OME1 showed 44.09% of drug 
release at the end of 12 hrs and emerged as best formulation. 
 
Basavaraja et al., (2015)
52
 Formulated and evaluated the sustained release matrix tablets of 
Flurbiprofen. By using the natural and synthetic polymers. Flurbiprofen is NSAID drug used 
extensively in the treatment of rheumatoid arthritis, degenerative joint disease, osteoarthritis, 
Ankylosing Spondylitis, acute musculoskeletal disorders, low back pain and allied conditions. 
The natural polymers are Xanthan gum, Karaya gum, and synthetic polymers like HPMC K- 
100, Ethyl cellulose were utilized in the formulation of matrix tablets containing Flurbiprofen by 
wet granulation technique and evaluated for its in-vitro drug release. Natural polymer is 
hydrophilic in nature and rate controlling polymers. Granules were prepared and evaluated for 
loose bulk density, tapped bulk density, compressibility index and angle of repose, showed 
satisfactory results. Formulation was optimized on the basis of acceptable tablet properties 
(hardness, friability, drug content and weight variations), in-vitro drug release and stability 
studies. All the formulations showed compliance with Pharmacopeial standards. The in-vitro 
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release study of matrix tablets were carried out in pH 1.2 HCl for 2 hours and pH 7.4 phosphate 
buffer for the remaining 10 hours as dissolution medium. Among all the formulation, F12 
showed 97.23% of drug which was better controlled release at the end of 12 hrs. It has been 
found that the optimized formulation F-12 containing 500 mg of ethyl cellulose better sustained 
effect for 12 hrs and emerged as best formulation. 
 
B. Manjula et al., (2016) 
53
 Formulated and evaluated the colon specific tablets of Ornidazole 
tablets were successfully prepared using enteric coated polymers eudragit, guar gum and HPMC 
k15m study of the preformulation charcteristics and FTIR studies indicates that there was no 
interaction between ornidazole and excipients used in the formulation. In-vitro release profiles of 
optimized form of F7 were found to showed delayed release pattern in a very customized manner 
which was very much required for the colon specific drug delivery. In-vitro release profiles of 
optimized formulation of ornidazole controlled release tablets (F-7) were found to be improvised 
and followed zero-order kinetics, hence the release of the drug from the dosage form was 
independent of concentration and followed Higuchi model, and hence release of drug from press 
coated tablet was by diffusion mechanism. The drug delivery system was designed to deliver the 
drug at such a time when it was needed nocturnal time. Formulation F7 showed 75.98% of drug 
release at the end of 10 hrs and emerged as best formulation. 
 
L. Matsyagiri et al., (2014)
54 
Formulated and evaluated the colon specific drug release of 
Albendazole with the purpose of developing a release of drug at colon region for local action, 
which is very convenient for administration, without the problem of enzymatic degradation and 
effect of pH of upper part of GIT like stomach and small intestine. Colon specific matrix tablets 
of Albendazole were prepared using guar gum, xanthene gum and HPMC polymers as matrix. 
FTIR showed that there is no interaction between drug and excipients. In-vitro dissolution of 
prepared matrix tablets of Albendazole performed by using USP type II apparatus in pH 0.1N  
first 2 hrs and remaining three hours in phosphate buffer pH 7.4 phosphate buffer solutions. The 
tablets were evaluated for various parameters like thickness, drug content uniformity, weight 
variation, hardness, friability and in-vitro drug release, all were showed satisfactory results. It is 
concluded that colon specific drug release of Albendazole give all satisfactory results for 
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formulation F1-F9. Formulation F7 showed 87.02% of drug release at the end of 12 hrs and 
emerged as best formulation. 
 
Patel Jayvadan K et  al., (2009)
55 
Developed the colon targeted drug delivery system by using 
Chitosan as a carrier for Mesalamine. Matrix tablets containing various excipients and Chitosan 
were prepared by wet granulation technique using different binder systems. The prepared tablets 
were evaluated for Hardness, Weight variation, Drug uniformity, Friability and In-vitro Drug 
release study. The surface of the device of best formulation was coated with Eudragit S100 to 
ensure that the device was more pH dependent and trigger the drug release only at higher pH. 
The final product is expected to have the advantage of being biodegradable and pH dependant. 
The matrix tablet containing Chitosan as a carrier and Hydroxypropyl methyl cellulose as binder 
was found to be suitable for targeting mesalamine for local action in the colon as compare to 
other matrix tablets containing different binders. Matrix tablets containing Chitosan released 97-
99% of mesalamine in simulated colonic fluid. The stability study for prepared tablets at 
40oC/75% relative humidity for three months showed no significant change in In-vitro drug 
release pattern. The results of in-vitro study indicate that matrix tablets containing Chitosan as 
carrier and Hydroxypropyl methyl cellulose as binder are most suitable to deliver the drug 
specifically in colonic region. The final formulation of mesalamine for colonspecific drug 
delivery gives pH, time and enzyme controlled release. All the parameters were found to be 
within the limits. Formulation F9 showed 90.25% at the end of 12 hrs and emerged as best 
formulation. 
 
Sam T Mathew et al., (2016)
56
 Formulated and evaluated the matrix tablets of albendazole 
containing various proportions (20%, 25%, 30% and 35%) of guar gum, xanthum gum and 
dextrin were prepared by direct compression technique using 10 mm concave punch. The 
prepared tablets were evaluated for hardness, friability, weightvariation, drug content uniformity 
and were subjected to in-vitro drug release with and without rat caecal content (4% w / v). All 
formulations (F1 - F12) which shows restricted drug release in stomach and small intestine and 
which shows more release in colonic environment. The drug release was independent of its 
concentration and the mechanism of drug release followed by super case-II transport. The 
accelerated stability studies revealed that there was no significant change in the colour, shape 
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and drug content. The formulation (F9) is most suitable to target colon without being released 
significantly in the stomach and small intestine, and also it may avoid systemic side effects in the 
gastrointestinal tract. All the parameters were found to be within the limits. Formulation F9 
showed 94.25% at the end of 12 hrs and emerged as best formulation. 
 
Shekhar singh et al., (2013)
57
 Developed the colon targeted matrix tablets of the drug 
Flurbiprofen. NSAIDS class of drug that is designed to for sustained effect. Different 
formulation (F1 TO F9) batches were made with the help of different polymers and their 
different proportions (Guar gum, Eudragit RL, Eudragit RS) with the help of Wet granulation 
technique. The prepared matrix tablets were evaluated in terms of their pre-compression 
parameters, physical characteristics like hardness, friability, uniformity of weight, uniformity of 
drug content, in-vitro drug release. The in-vitro release study had been done into simulated 
gastric and intestinal fluid with a new method. From this study we concluded that the batch F7 
showed good results then the other batches. The batch F7 showed maximum prolonged drug 
release 97.34% upto 12 hrs and emerged as best formulation. 
 
K. Ramesh Reddy et al., (2015)
58
 Formulated the Prednisolone matrix tablets for colon 
targeting drug delivery system by using pectin and chitosan polymers. Prednisolone is synthetic 
Glucocorticoids, a derivative of cortisol, which is used to treat a variety of inflammatory and 
auto-immune conditions. Colon targeted drug delivery is an active area of research for local 
diseases affecting the colon, as it improves the efficacy of therapeutics and enables localized 
treatment, which reduces systemic toxicity. Targeted delivery of therapeutics to the colon is 
particularly advantageous for the treatment of inflammatory bowel disease (IBD), which includes 
ulcerative colitis and Crohn's disease. Prednisolone matrix tablets were prepared by wet 
granulation technique by using different polymers such as chitosan and pectin are sustained 
release polymers. Starch mucilage is a granulating agent .The matrix tablets were evaluated their 
compatibility studies by using FT-IR, micromeritics properties, post formulation characters, 
stability and in-vitro dissolution studies. The batch F2 showed maximum prolonged drug release 
96.79% at the end of 12 hrs and emerged as best formulation. 
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G. Subba Rao et al., (2013)
59 
Formulated the controlled release tablet of Diltiazem 
hydrochloride for colon targeting tablets using gum kondagogu. The drug excipient interaction 
studies were carried out by FTIR, DSC, and XRD studies.The prepared matrixes showed 
controlled delivery for over 18hrs.Studies were also carried out in presence of 4% w/v RCC. In- 
vitro drug release studies showed that F6 released 92%, 94% in stimulated colonic fluid and 98% 
in stimulated colonic fluid in presence of rat cecal content in a controlled manner over a period 
of 18 hours. Formulation F6 was optimized and put for Stability studies. Stability studies 
revealed that matrix tablets were stable over a period of 6 months. All the formulation followed 
zero order release kinetics and fit into peppas model of drug release. The batch F6 showed 
maximum prolonged drug release 98.34% upto 12 hrs and emerged as best formulation. 
 
Satinder Kakar et. al, (2014)
60 
Developed the colon targeted drug delivery system by using 
Chitosan, Eudragit S 100 and Ethylcellulose and to compare the results obtained by three 
different carrier systems. Results obtained were fitted to different mathematical models to 
estimate which model fits best to the drug release. Wet granulation technique was employed for 
the preparation of prolonged release matrix tablets. Tablets containing chitosan as carrier system 
were found to show prolonged release in the colon. Kinetic models were applied among which 
Higuchi model suits best. 
 
Prasanta Kumar Choudhury et al., (2012)
61
  Formulated the colon specific drug delivery of 
Ornidazole . The formulation of colon specific drug delivery system (CDDS) was designed such 
that the innermost part consists of an immediate release core tablet of Ornidazole which is then 
compression coated with a pH-independent hydrophilic polymer (Hydropropylmethyl cellulose-
HPMC K4M). This is then coated with a pH-dependent methacrylic acid copolymer (Eudragit 
S100). The optimized concentration (coating level) of Eudragit S100 provides an enteric coat 
that protects the tablet from the hostile environment of stomach and is targeted to the colon. The 
coating thickness and core to coat ratio of HPMC were optimized to set a desired lag time in the 
intestine. The evaluation parameters and in-vitro drug release data attests that the developed 
CDDS can exhibit site-specific drug delivery to the colon. The batch F7 showed maximum 
prolonged drug release 98.34% upto 12 hrs and emerged as best formulation. 
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Magdum Sonali Vijaykumar et al., (2016)
62 
Formulated and evaluated the colon targeted tablet 
by using various proportion of guar gum. Budesonide drug was selected for this research work. 
The Budesonide which is used for treating colonic diseases. The tablet was formulated by using 
Guar gum, Lactose Starch, Talc and Magnesium Strearate.The tablets were evaluated for 
thickness, hardness and friability and all this was found to be in within range. The in-vitro 
dissolution study was carried out by using different PH of phosphate buffer solution as 250 ml 
HCL buffer PH 1.2 for 2 hr., 250 ml phosphate buffer PH 6.8 for another 3hr.and finally250 ml 
PBS PH7.4 till the end of 12hr.The drug release of all the formulation was found to be within 
range of 92.23 to 98.38%.tablet was capable to release drug at colon and protect the tablet from 
acidic PH. The batch F3 showed maximum prolonged drug release 98.38% upto 24 hrs and 
emerged as best formulation. 
 
Dr. T. Satyanarayana  et al., (2017)
63
 Formulated and Evaluated the Mesalazine colon targeted 
matrix tablets was done by using various polymers. To achieve pH independent drug release of 
Mesalazine, pH modifying agents (buffering agents) were used. Colon targeted tablets were 
prepared in two steps. Initially core tablets were prepared and then the tablets were coated by 
using different pH dependent polymers. Ethyl cellulose, Eudragit L100 and S100 were used as 
enteric coating polymers. The precompression blend of all formulations was subjected to various 
flow property tests and all the formulations were passed the tests. The tablets were coated by 
using polymers and the coated tablets were subjected to various evaluation techniques. The 
tablets were passed all the tests. Among all the formulations F7 formulation was found to be 
optimized as it was retarded the drug release up to 12 hours and showed maximum of 97.87% 
drug release. It followed first order kinetics mechanism. Stability studies was Performed no 
chemical changes was occurred 
 
Srilakshmi N  et al., (2015)
64
 
 
Formulated and Evaluated the Metronidazole enteric coated 
tablets for colon targeting .Colon specific drug delivery has gained importance for the delivery at 
colonic region by use of various drugs to treat both local and systemic diseases. Local diseases 
include Chron’s disease, ulcerative colitis, colorectal cancer, amoebiasis etc. The active 
ingredient Metronidazole has to be delivered to the colon for effective action against 
trophozoites of E. histolytica and Giradia lamblia, wherein the respective trophozoites reside in 
Chapter 3                                                                                                         Review of Literature 
 
S.B.C.P                                             Department of pharmaceutics Page 49 
 
the lumen of caecum and large intestine and adhere to colonic mucus and epithelial layers. 
Formulating Metronidazole as conventional tablets give side effects which occur due to 
absorption of drug from upper part of GIT and the pharmacokinetic profile of Metronidazole 
indicates that the drug is completely absorbed in approximately 1 hr after a single dose. So, 
various synthetic hydrophilic polymers are used to control the drug delivery and target the drug 
to the intestine using enteric coated polymers. The present study aimed to formulate the core 
tablets using different polymers such as HPMC K 15M and HPMC K100M in different ratios 
and the core tablets were coated with an enteric polymer. The prepared tablets were evaluated for 
weight variation, hardness, friability, content uniformity and in-vitro drug release study first in 
0.1N HCl followed by in pH 7.4 phosphate buffer. Formulation F12 showed good targeted site 
controlled drug delivery, as it showed 96% drug release for 24 hrs and emerged as best 
formulation. 
 
.J. R. Jadhav et al., (2012)
65 
Formulated and evaluated the colonic compression coated tablet of 
budesonide. The in-vitro performance of compress coated tablet of Budesonide. A novel colon 
targeted tablet formulation was developed by press coating of Budesonide with guar gum and 
Eudragit S-100 as barrier layer. The entire device was enteric coated so that variability in gastric 
emptying time can be overcome and a colon specific release can be achieved. Different ratios of 
polymers were selected to achieve suitable lag time for the treatment of Crohn’s disease and 
ulcerative colitis. In-vitro release studies for prepared tablets were carried out for 2 h in 1.2 pH 
phosphate buffer, 3 h in pH 6.8 phosphate buffer and 6 h in simulated colonic fluid. In vitro 
studies revealed that the tablet coated with guar gum and Eudragit S-100 have limited drug 
release in stomach and small intestinal environment and released maximum amount of drug in 
the colonic environment. Colon specific release has been achieved from tablet of F5 formulation 
which not given release in stomach and small intestine and about 98.87% drug release in the 
colon. Formulation F5 showed good targeted site controlled drug delivery, as it showed 98.87% 
drug release for 24 hrs and emerged as best formulation. 
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4.1. LIST OF CHEMICALS USED 
Table No: 2 
 
 
 
 
 
 
 
 
S.No  Name of Ingredients Category  Manufacturer/Suppliers 
1 Ibuprofen Drug Shasun chemicals, Chennai. 
2 Eudragit S100 polymer Vikram Thermo (India) LTD 
Ahmedabad. 
3 Ethyl cellulose polymer Jalan cellulose. Co, India. 
4 Lactose (DCL 21) Diluent Cabot sanmar LTD, Chennai. 
5 Talc Lubricant Abishek organics, Mumbai. 
6 Magnesium stearate Lubricant Amishi Drugs and Chemicals, 
Gujarat. 
7 Eudragit FS 30D Enteric coating  flim former Vikram Thermo (India) LTD 
Ahmedabad. 
8 Tri Ethyl Citrate Plasticizer Chemtrec –International LTD 
9 Purified talc Anti tacking agent Abishek organics, Mumbai. 
10 Purified water Vechicle Fourrts india, Chennai 
  
 
Drug profile 
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4.2. DRUG PROFILE 
IBUPROFEN  
 
GENERAL DESCRIPTION 
66, 67, 68
 
 Structural formula:    
                                                                                    
Chemical name                            : (RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid. 
Molecular formula                      : C13H18O2 
Molecular weight                        : 206.29 g/mol 
Therapeutic category                 : Anti-inflammatory, analgesic, prostaglandin synthesis inhibitor. 
Description                                  : A white or almost white, crystalline powder or colourless crystals 
                                                          Odourless. 
Melting point                               : 75.0
0 
C to 77.5
0 
C 
Boiling point                                : 157 °C 
Dose                                              : 200mg to 1.2g daily, in divided doses, after food. 
Storage                                         : Stored at room temperature, between 15-30
0
C. 
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SOLUBILITY:    
Soluble in ethanol,chloroform,ether,acetone,aqueous solutions of alkalihydroxide and carbonate, 
dichloromethane, methanol,ethyl acetate.Insoluble in water. 
MECHANISM OF ACTION
69, 70
: 
Ibuprofen, it is a Non Steroidal Anti-inflammatory Drug (NSAID) coming under the class of propionic 
acid derivatives. It is a potent analgesic, antipyretic and anti-inflammatory drug. It has poor uricosuric 
effect. It is a potent prostaglandin synthesis inhibitor like aspirin. It has antiplatelet action. 
                        The main action of this drug is inhibition of arachidonate cyclo-oxygenase. 
Ibuprofen,which binds reversibly to the enzyme competing with the natural substrate (arachidonic 
acid),has a rapid, reversible competitive inhibition. This action is manifested by the propionic acid 
NSAIDs. 
PHARMACODYNAMICS
71
:  
Analgesic, Anti-inflammatory, and Antipyretic actions. Ibuprofen inhibits prostaglandin synthesis.   
PHARMACOKINETICS
72
: 
All propionic acid derivatives enter brain, synovial fluid, and cross placenta.     
 Absorption            : Part of oral dose is absorbed from gastrointestinal tract. 
 Distribution           : Highly protein-bound. 
 Metabolism            : Undergoes biotransformation in the liver. 
 Excretion               : Excreted mainly in urine, and some in bile. 
Oral absorption                     : 98-99% 
Onset of action                     : 30-60 min 
Duration                                : 4-6 hrs 
Plasma half life                     : 2-4 hrs 
Plasma protein bound           : 99% 
Excretion                               : 90% 
Metabolites                            : Hydroxylated and carboxylated compound. 
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CONTRAINDICATIONS AND PRECAUTIONS: 
Contraindicated in patient with hypersensitivity to drug or in those who have the syndrome of nasal 
polyps, angioedema and bronchospastic reaction to aspirin or other Non Steroidal Anti inflammatory 
Drugs (NSAIDs) Use cautiously in patients with impaired renal or hepatic function, gastrointestinal 
disorders, peptic ulcer disease, cardiac decompensation, hypertension or coagulation defects. 
Chewable tablets conain aspartame, use cautiously in patients with phenylketonuria. Ibuprofen is 
contraindicated during the last trimester of pregnancy because it may cause problems with the fetus, 
or complication during delivery. 
ADVERSE REACTIONS
73
: 
Central nervous                       : Headache, Dizziness, Nervousness, Aseptic meningitis. 
Cardiovascular                         : Peripheral edema, fluid retention, edema. 
Gastrointestinal                        : Epigastric distress, nausea, occult blood loss, peptic ulceration. 
Genitourinary                           : Acute renal failure, azotemia, cystitis, hematuria. 
Hematologic                             : Prolonged bleeding time, anemia, neutropenia, pancytopenia, 
                                                    Thrombocytopenia, Aplastic anemia, Leucopenia, agranulocytosis. 
Hepatic                                      : Elevated enzymes. 
Respiratory                                : Bronchospasm. 
Skin                                            : Pruritus, rash, urticaria, Stevens – Johnson syndrome. 
DRUG INTERACTIONS: 
With Acetyl CoA Enzyme inhibitors : Reduced response when used together; may result in  
                                                                   Acute reduction in renal function. 
With Antacids                                       : May decrease the absorption of Ibuprofen. 
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Aspirin                                                   : May decrease the bioavailability of Ibuprofen. 
Coumarin derivatives, 
Nifedipine,phenytoin,verapamil          : Toxicity may occur with concurrent us Avoid use together. 
Diuretics, antihypertensives                 : Concurrent use may decrease effectiveness of these drugs; 
                                                                     Diuretics may increase nephrotoxicity. 
Other anti-inflammatory agents          : Increased nephrotoxicity may occur. 
Insulin or oral antidiabetic agents       : May potentiate hypoglycemic effects. 
Lithium, Methotrexate                          : Decreased renal clearance of these drugs. 
USES
74
: 
 As an analgesic in painful conditions. 
 In fever. 
 In gout. 
 For soft tissue injuries, fractures, following tooth extraction. 
 To relieve postoperative pain, dysmenorrhoea and osteoarthritis. 
  
 
Excipients profile 
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4.3 EXCIPIENTS PROFILE
75
 
EUDRAGIT S100 
Table No: 3 
S.NO PROPERTIES DESCRIPTION 
1 Synonyms Polymeric methacrylates 
2 Chemical name Poly (methacrylic acid-co-methyl methacrylate) 1:2 
3 Structural formula 
  
4 Molecular weight approx. 125,000 g/mol 
5 Melting point 160
0
C  
6 Description It occurs as a fine white free flowing powder 
7 Solubility 
Soluble in acetone and alcohols and 1N NaOH. EUDRAGIT 
S 100 is practically insoluble in ethyl acetate, methylene 
chloride, petroleum ether and water. 
8 Functional category Film former, Tablet binder, Tablet diluents 
10 Application 
Used as enteric coating agents because they are resistant to 
gastric fluid 
11 Stability 
Dry powder polymer forms are stable at temperature less 
than 30
0
C. Above this temperature, powders tend to form 
clumps, although this does not affect the quality of the 
substances and the clumps can readily be broken up. Dry 
powders are stable for at least 3 years if stored in a tightly 
closed container at less than 300C 
12 Incompatibilities 
Incompatibilities occur with certain polymethacrylate 
dispersions depending upon the ionic and physical properties 
of the polymer and solvent. 
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ETHYL CELLULOSE 
Table No: 4 
S.NO PROPERTIES DESCRIPTION 
1 Synonyms Aquacoat, Ethocel 7cP,ethyl cellulose, Surelease 
2 Chemical name Cellulose ethyl ether 
3 Molecular formula C20H38O11 
4 Molecular structure 
                  
5 Molecular weight 454.513g/mol 
6 Melting point 240-255 
7 Description Free- flowing, white to light tan- colored powder 
8 Solubility 
Practically insoluble in water in glycerol and in 
propylene glycol, but soluble in varying proportions in 
certain organic solvents depending upon the ethoxyl 
content. 
9 Functional category 
Coating agent, Flavoring agent, Tablet binder, Tablet 
filler 
10 Application 
The main use of Ethyl cellulose in oral formulation is 
as a hydrophobic coating agent for tablets and 
granules. Ethyl cellulose coating is used to modify the 
release of drug and to mask an unpleasant taste or to 
improve the stability of a formulation. 
11 Incompatibilities 
Incompatible with paraffin wax and microcrystalline 
wax 
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LACTOSE DCL 21 
Table No: 5 
S.NO PROPERTIES DESCRIPTION 
1 Synonyms 
Lactose Anhydrous NF DCL-21, Pharmatose DCL21, 
Lactosum. 
2 Chemical name Alpha- lactose, Anhydrous lactose. 
3 Molecular formula C12H22011 
4 Molecular structure 
         
4 Molecular weight 342.30g/mol 
5 Melting point 202.8
0
C 
6 Description 
White to off white crystalline particles or powder, 
odourless and slightly sweet tasting. 
7 Solubility Soluble in water, Sparingly soluble in ethanol. 
8 Functional category Used in the direct compression of tablets (tablet binder) 
9 Application 
Anhydrous lactose is widely used in direct compression 
tableting application and as a tablet and capsule filler and 
binder. Anhydrous lactose can be used with moisture 
sensitive drugs due to its low moisture content. 
10 Incompatibilities Lactose is incompatible with strong oxidizers. 
11 Stability 
Anhydrous lactose should be stored in a well closed 
container in a cool, dry place. 
  
Chapter 4                                                                                                    Materials and methods 
 
S.B.C.P                                             Department of Pharmaceutics Page 58 
  
 
PURIFIED TALC 
Table No: 6 
S.NO PROPERTIES DESCRIPTION 
1 Synonyms 
Altalc; E553; hydrous magnesium calcium silicate; 
Luzenac Pharma; Magsilosmanthus; Magsil Star; 
Powdered talc; Purified French chalk; soapstone; 
Steatite; Superior. 
2 Chemical name Talc  
3 Molecular formula Mg6 (Si2O5)4(OH)4 
4 Molecular weight 379.3 g/mol 
5 Melting point 93
0 
C 
6 Description 
Talc is a very fine, white to greyish-white, odourless, 
impalpable, unctuous, crystalline powder. It adheres 
readily to the skin and is soft to touch and free from 
grittiness.  
7 Solubility 
Practically insoluble in dilute acids and alkalis, 
organic solvents and water. 
8 Functional category 
Anti-caking agent, glidant, tablet and capsule diluent, 
tablet and capsule lubricant 
9 Application 
It is widely used as a dissolution retardant in the 
development of controlled release products. Talc is 
also used as lubricant in tablet formulations, coating 
for pellets and as an adsorbent in topical preparations. 
Talc is used as a dusting powder and also used to 
clarify liquids and it is mainly used in food and 
cosmetic products as a lubricant. 
10 Incompatibilities Incompatible with quaternary ammonium compounds. 
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MAGNESIUM STEARATE 
Table No: 7 
S.NO PROPERTIES DESCRIPTION 
1 Synonyms Magnesium octadecanoate, stearic acid, magnesium salt. 
2 Chemical name Octadecanoate stearic acid magnesium salt 
3 Molecular structure [CH3 (CH2 )16 COO]2 Mg 
4 Molecular weight 591.27g/mol 
5 Melting point 88
0
C 
6 Description 
It occurs as a fine, white precipitated or milled impalpable 
powder with a faint odour and a characteristic taste. 
7 Solubility 
Practically insoluble in ethanol, ether and water, slightly 
soluble in warm benzene and warm ethanol (95 %). 
8 Functional category Lubricant. 
10 Application 
It is widely used in cosmetics, food, pharmaceutical 
formulations. It is primarily used as lubricant in capsule 
and tablet manufacture at concentrations between 0.2-5.0 
percent. 
11 Stability 
It is stable and should be stored in a well closed container in 
a cool and dry place. 
12 Incompatibilities It is incompatible with strong acids, alkalis and iron. 
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EUDRAGIT FS 30D 
Table No: 8 
S.NO PROPERTIES DESCRIPTION 
1. Chemical name 
Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic 
acid) 
2. Molecular structure 
 
3. Molecular weight 280000 g/mol 
4. Description Milky-white liquid of low viscosity with a faint characteristic odour. 
5. Solubility 
The dispersion is miscible with water in any proportion, the 
milky-white appearance being retained. A clear or slightly 
cloudy, viscous solution is obtained by mixing 1 part Eudragit 
FS 30 D with 5 parts acetone. The same results are obtained by 
mixing with ethanol or isopropyl alcohol; initially, the polymer 
is precipitated, but then dissolves again in the excess organic 
solvent. A clear or slightly cloudy liquid is obtained by mixing 1 
part Eudragit FS 30 D with 2 parts 1 N sodium hydroxide. 
6. Application Used as enteric coating agents because they are resistant to 
gastric fluid. 
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4.4. LIST OF EQUIPMENTS USED 
Table No: 9 
S. No 
 
Name of the Equipment 
 
Manufacturer 
1. Weighing balance Shimadzu 
2. Bulk density apparatus Thermonik 
3. Compression machine (8 station) Accura 
4. Coating pan Electro lab 
5. Hardness tester Thermonik 
6. Thickness tester Mitutoyo corps, Japan 
7. Friability tester Electro lab 
8. Disintegration apparatus Electro lab 
9. Dissolution apparatus Lab india 
10. I.R moisture balance Citzen 
11. pH analyzer  Lab india 
12. FTIR Spectrophotometer 8300 Perkin Elmer 
13. U.V spectrophotometer Shimadzu 
14. Ultra Sonicater Lab man scientific instrument 
15. Electromagnetic Sieve Shaker Electro pharma 
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4.5 METHODOLOGY 
 
4.5.1. PREFORMULATION STUDIES:
 76
 
Preformulation is the first step in the rational development of dosage form of a substance 
and is defined as an investigation of physical and chemical properties of drug substance alone 
and when combined with excipients. This initial learning phase is known as preformulation. 
The basic purpose of the preformulation activity is to provide a rational basis for the 
formulation approaches, to minimize the chances of success in formulating an acceptable product 
and to ultimately provide a basis for optimizing drug product quality and performance. The first 
step in any formulation activity is careful consideration of a complete physicochemical profile of 
the active ingredients available, prior to initiating a formulation development activity.
 
 
CONTENTS OF PREFORMULATION STUDIES: 
 Background – Compound chemical name, chemical structure, solvent of recrystallization, 
purity, therapeutic category. 
 Organoleptic properties – Appearance, colour and odour. 
 Microscopic examination – Crystal habit, crystal shape and size. 
 Physical properties – Density, particle size, surface area, flow properties, hygroscopicity. 
 Solvent properties – pH of solution, solubility and dissolution rate, drug excipient 
compatibility study. 
 
IMPORTANT PARAMETERS EVALUATED DURING PREFORMULATION 
STUDIES: 
1. Evaluation of API 
The Evaluation of Ibuprofen was done according to IP. Following are some of the 
important parameters evaluated during preformulation studies and results are tabulated in 
Table No: 22 
 
A. Description 
It is the initial evaluation during preformulation studies which assess the colour of 
the substance. This was only a descriptive test. 
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B. Solubility 
Aqueous solubility is an important physicochemical property of drug substance, 
which determines its systemic absorption and in turns its therapeutic efficacy. 
 
SOLUBILITY SPECIFICATIONS 
Table No: 10 
Descriptive terms 
Approximate volume of solvent in 
milliliters per gram  of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble More than 10,000 
 
C. Melting point 
The temperature at which the first particle of the substance completely melts is 
regarded as melting point of the substance. The temperature at which the first particle start 
to melt and last particle completely melts is regarded as melting range. Melting point of 
Ibuprofen was conducted as per monograph.  
 
D. Loss on drying 
The loss on drying test is designed to measure the amount of water and volatile 
matters in a sample when the sample is dried under specified conditions. Loss on drying 
of Ibuprofen was measured by using moisture balance. Weigh approximately 2gm of 
Ibuprofen and placed into a plate of moisture balance. Set the temperature to 45°C. 
Measure the moisture content of drug in percentage. 
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E. Flow Properties (Angle of Repose) 77 
Angle  of  repose  is  defined  as  the  maximum  angle  possible  between the surface 
of the pile of the powder and  horizontal  plane. The angle  of  repose  of  the powder  or  
granules  was  determined  by  fixed  funnel  method. To assess  the  flow  property  of  
the  powder  granules, the  height  of  the  funnel   was  adjusted  in  such  a way  that  the  
tip  of  the  funnel  just  touches  the  apex  of  the  heap  of  the  powder or granules  
above  a  paper  that   was   placed on a flat horizontal surface.  Accurately weighed 
powder blend was taken in a beaker. It was allowed to flow through the funnel freely on 
the surface of the paper to form a cone shaped pile. The diameter of the cone (d) and the 
height (h) of the pile was noted. From the diameter, radius (r) was calculated. The angle 
of repose (θ) was calculated using the following formula. The results were tabulated in 
Table No: 23. 
Ө = tan –1(h/r) 
 
ANGLE OF REPOSE AS AN INDICATION OF POWDER FLOW PROPERTY 
Table No: 11 
 
 
 
 
 
 
 
 
 
 
 I. Bulk density 
Bulk density is a characteristic of a powder rather than individual particles and is given 
by the mass M, of the powder occupying a known volume, Vo.
 
It is expressed in g/ml. An 
accurately weighed quantity of granules was transferred into a 50 ml measuring cylinder with 
Flow properties Angle of repose (degree) 
Excellent 25-30 
Good 31-35 
Fair  36-40 
Passable  41-45 
Poor 46-55 
Very poor 56-65 
Extremely poor >66 
Chapter 4                                                                                                     Materials and methods 
 
S.B.C.P                                                   Department of Pharmaceutics Page 65 
 
the aid of the funnel. The unsettled apparent volume, to the nearest graduated unit occupied by 
the granules was measured. Bulk density was determined using the formula.
 78
 The results were 
tabulated in Table No: 24. 
ρbulk = m/Vo 
       Where, 
               ρbulk = Bulk density; 
                m = Mass of the blend  
              Vo = Untapped Volume 
 
J. Tapped density: 
Tapped density is achieved by mechanically tapping a measuring cylinder containing a 
powder sample. After observing the initial volume, the cylinder is mechanically tapped, and 
volume readings are taken until little further volume change is observed. The measuring cylinder 
containing a weighed quantity of granules (after measurement of bulk density) was subjected to 
500 taps in tapped density tester (Electro Lab USP II). The tapped density was calculated by 
using the formula. The results were tabulated in Table No: 24. 
ρt = m/Vt 
Where, 
 ρt = Tapped density; 
 m = Mass of the granules  
  Vt = Final tapped volume. 
 
4.5.2 MEASUREMENT OF POWDER COMPRESSIBILITY 
 Carr’s compressibility index: 
Compressibility index are a measure of the tendency for arch formation and the ease 
with which the arches will fail.
 
Table No: 12 show the relationship between compressibility 
index and flowability. The results were tabulated in Table No: 25. It is calculated by using the 
formula.
79
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CI = ρt – ρbulk / ρt × 100 
 Where, 
            CI =  Compressibility index 
          ρbulk = Bulk density  
          ρt = Tapped density 
 
CARR’S COMPRESSIBILITY INDEX: 
Table No: 12 
 
 
 
 
 
 
 
 
 
 Hausner’s ratio: 
    Hausner found that the ratio ρt / ρbulk was related to interparticle friction and, as such 
could be used to predict powder flow properties. He showed that powders with low interparticle 
friction, such as coarse spheres, had ratios of approximately 1.2; whereas more cohesive, less 
free flowing powders such as flakes have values greater than 1.6. Table No: 13 shows the flow 
characters and corresponding Hausner’s ratio. The results were tabulated in Table No: 25. It is 
calculated using the formula.
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Hausner’s Ratio = ρt / ρbulk 
                 Where,  
                          ρbulk = Bulk density  
                          ρt  = Tapped density 
S. No. Compressibility index (%) Flow characters 
1 < 10 Excellent 
2 11-15 Good 
3 16-20 Fair 
4 21-25 Passable 
5 26-31 Poor 
6          32-37          Very poor 
7        >38          Extremely poor 
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HAUSNER’S RATIO AS AN INDICATION OF POWDER FLOW 
Table No: 13 
S. No. Hausner’s ratio Type of flow 
1 1.0 –1.11 Excellent 
2 1.12 –  1.18 Good 
3 1.19 – 1.25 Fair 
4 1.26 – 1.34 Passable 
5 1.35  – 1.45 Poor 
6 1.46 - 1.59 Very poor 
7 >1.60 Extremely poor 
 
 Particle Size Analysis 
In case of tablets, size influences the flow and the mixing efficiency of powders and 
granules. Size can also be a factor in stability. Fine materials are relatively more open to attack 
from atmospheric oxygen, the humidity and interacting excipients than are coarse materials. 
Particle size distribution of the drug was estimated by sieving method. The sieves are 
stacked on top of one another in ascending degrees of coarseness. The test powder, for example 
10gm, was placed on the top sieve. The nest of sieves was subjected to a standard period of 
agitation. The weight of material retained on each sieve was accurately determined. Percentage 
of powder retained on each sieve was calculated by using the following formula. The results 
were tabulated in Table No: 26. 
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CLASSIFICATION OF SAMPLE BASED ON THE PERCENTAGE OF SAMPLE 
RETAINED OR PASSED ON TEST SIEVES 
Table No.14 
S. No. Nature of sample Result of determination 
1 Coarse powder 
NLT 95% of the sample mass pass through #14 
and NMT 40% pass through #36 
2 Moderately coarse powder 
NLT 95% of the sample mass pass through #25 
and NMT 40% pass through #60 
3 Moderately fine powder 
NLT 95% of the sample mass pass through #36 
and NMT 40% pass through #100 
4 Fine powder 
NLT 95% of the sample mass pass through #100 
and NMT 40% pass through #150 
5 Very fine powder 
NLT 95% of the sample mass pass through #150 
and NMT 40% pass through #200 
6 Super fine powder 
NLT 90% by number of particles are less than 
10µm 
 
2. DRUG-EXCIPIENT COMPATIBILITY STUDIES
 
 
  In the tablet dosage form the drug is in intimate contact with one or more excipients; the 
latter could affect the stability of the drug.  Knowledge of drug- excipient interactions is 
therefore very useful to the formulator in selecting appropriate excipients. This information may 
be present for known drugs. For new drugs or new excipients, the preformulation scientist must 
generate the needed information. 
A. Physical observation: 
 Active ingredient was mixed well with all excipients in binary ratio and small portion of 
this mixed powder was placed in a 2ml of cleaned and dried vial. This vial was kept for 
observation in stability chamber at 40
o
C ± 2
o
C / 75 ± 5% RH. Mixtures were also placed at     
2
o
C -8
o
C, 50
o
C and room temperature (Control). Physical observation has been carried out 
visually at the initial stage, after 15 days and after 1 month at 40
o
C ± 2
o
C / 75 ± 5% RH. The 
results were tabulated in Table No: 27. 
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DRUG-EXCIPIENT COMPATIBILITY STUDIES 
Table No: 15 
S. No Drug and excipients Parameter 
1 Ibuprofen Colour change 
2 Ibuprofen + Excipients Colour change 
                                   
                  B. Chemical compatibility studies by FT- IR: 
  Physical compatibility studies were assured by FT-IR studies. The pure drug sample, 
drug-excipient mixtures of the formulation were chosen for the study. The FT-IR spectra’s of the 
above samples were studied after a period of 30 days from preparation of the mixtures, to 
facilitate prompt detection of incompatibility. The spectra’s were obtained by preparing 
Potassium bromide pellets under dry condition by using pellet press.  
The spectra of the pure drug sample and that of the drug-excipient mixtures were 
compared to check the incompatibility problems. If there are no changes in peaks of mixture 
when compared to pure drug, it indicates the absence of chemical interaction. The FT-IR 
spectra’s were as shown in Figure No: 9, 10. 
 
4.5.3 PREPARATION OF GRANULES FOR COMPRESSION 
Matrix tablet of Ibuprofen was prepared by direct compression method. All tablet 
ingredients was accurately weighed as mentioned in Table No. 16. The average weight of each 
uncoated tablet was 450 mg.  
 
Formulation of colon targeted matrix tablet of Ibuprofen. 
The method used in the formulation of colon targeted matrix tablet of Ibuprofen was direct 
compression method .All the batch formulations in these studies are formulated by direct 
compression method. 
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 Weighing: 
A required quantity of raw materials was weighed accurately. 
 Sifting: 
The Ibuprofen, eudragit S100 and ethyl cellulose were sifted using 60 # mesh. Lactose 
(DCL 21) sifted through 40 # mesh.  
 Mixing: 
The sifted powders were mixed in polythene bag for ten minutes. 
 Lubrication: 
The above dried granules were lubricated by using Talc. Talc is sifted through 40# mesh 
and magnesium stearate, sifting through 60# mesh after that mixed for 5 minutes in 
polythene bag. 
 Compression: 
Then final lubricated blend was compressed at an average weight of 450 mg using punch 
size 14.2 mm. 
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FORMULATION FLOWCHART OF IBUPROFEN MATRIX TABLETS BY DIRECT 
COMPRESSION METHOD 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                             
 
 
 
 
  
Sifting 
 
Mixing 
Lubrication 
Compression 
Weighing 
A required quantity of raw materials 
was weighed accurately. 
 
The Ibuprofen, Eudragit S100 and Ethyl 
cellulose are sifted using 60 # mesh. 
Lactose (DCL 21) sifted through 40 # mesh.  
 
The sifted powders are mixed in polythene 
bag for ten minutes. 
 
 
The above dried granules are lubricated by 
using Talc. Talc is sifted through 40# mesh 
and magnesium stearate, sifting through 60# 
mesh after that mix for 5 minutes in polythene 
bag. 
 
 
 
Then final lubricated blend is compressed at an 
average weight of 450 mg using punch size 
14.2 mm. 
 
 
 
Finally coated with Eudragit FS 30 D. 
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FORMULATION TRIAL BATCHES 
Table No: 16 
S. No INGREDIENTS 
QUANTITY OF INGRIDIENTS  (mg/tab) 
F1 F2 F3 F4 F5 F6 
1 Ibuprofen 250 250 250 250 250 250 
2 Eudragit S-100 80 60 50 35 20 14 
3 Ethyl cellulose 60 55 40 25 15 10 
4 Lactose (DCL 21) 50 75 100 130 154 165 
5 Talc 5 5 5 5 5 5 
6 Magnesium  stearate 5 5 5 5 6 6 
Total weight (mg) 450 450 450 450 450 450 
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PERCENTAGE OF INGREDIENTS USED IN TRIAL BATCH FORMULATIONS 
Table No: 17 
S. No INGRIDIENTS 
QUANTITY OF INGRIDIENTS  (%/tab) 
F1 F2 F3 F4 F5 F6 
1 Ibuprofen 55.55 55.55 55.55 55.55 55.55 55.55 
2 Eudragit S-100 17.77 13.33 11.11 7.77 4.44 3.11 
3 Ethyl cellulose 13.33 12.22 8.88 5.55 3.33 2.22 
4 Lactose (DCL 21) 11.11 16.66 22.22 28.88 34.22 36.66 
5 Talc 1.11 1.11 1.11 1.11 1.11 1.11 
6 Magnesium  stearate 1.11 1.11 1.11 1.11 1.33 1.33 
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4.5.4 COATING FORMULA: 
 
Composition of   Ingredient for Enteric Coating 
 
6% coating has been given for all the formulations to protect the drug from acidic environment. 
Table No: 18 
S. No Ingredients Quantity/1000 Tablet ( gm ) 
1 Eudragit FS 30 D 125 
2 Triethyl citrate 1.875 
3 Talc 18.75 
4 Purified water 120 
 
 
Preparation of Enteric Coating solution: 
A required quantity of Eudragit FS 30 D was weighed accurately and stirred. Mean while 
Triethylcitrate was added to it, purified talc were triturated separately in a motar. And added to 
the solution and stirred. Finally the volume were make up to required quantity with purified 
water. Filtered the above solution with #100 mesh. 
 
Weight built up calculation for enteric coating: [6 %] 
450 x 6 % (6 gm  100ml) 0.06 =27 
450 + 27 = 477 
The weight of enteric coated tablet = 477mg. 
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Coating Parameters 
                                               
Operation Condition for Enteric Coating Process 
Table No: 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5.5 EVALUATION OF POWDER BLEND 
The powder blends were evaluated for the following parameters before compression into 
tablets. 
1. Angle of repose  
2. Bulk density   
3. Tapped density  
4. Compressibility index and Hausner’s ratio. 
5. Moisture content. 
These procedures are discussed earlier in preformulation studies. The results were 
tabulated in Table No: 30. 
  
 
Specifications 
Enteric  coating range 
Pan diameter 12 
Speed of pan revolution 10-12 rpm 
Distance of spray gun 5-6 
Spray nozzle diameter 1.2 mm 
Spray rate 1.5 -2.0 ml /min 
Dry air temperature 50  ± 5
0
C / 30 mins 
Coating time 4 hours 
Bed temperature 30-40
0
C 
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4.5.6 EVALUATION OF POST-COMPRESSION PARAMETERS: 
The compressed tablets were evaluated for the following parameters. 
General appearance 
  The tablets should be free from cracks, depression, pinholes etc. the color and polish of 
the tablets should be uniform on whole surface. The surface of the tablets should be smooth. The 
results were tabulated in Table No: 31. 
 
Hardness: 
  Tablets require a certain amount of strength or hardness to withstand mechanical shocks 
of handling in manufacture, packaging, and shipping. Tablet hardness has been defined as, the 
force required to break a tablet in a diametric compression test
81
.Tablet hardness of all the 
formulations was measured using a Monsanto hardness tester. 
 
Thickness: 
Tablet thickness is an important parameter to be controlled to facilitate packaging. Tablet 
thickness, at constant compressive load, varies with changes in die fill, with particle size     
distribution and packing of the particle mix being compressed; whereas at constant die fill, 
thickness varies with variations in compressive load. Tablet thickness must be controlled within 
a ±5% variation of a standard value. Any variation within a particular lot should not be apparent 
to the unaided eye of the consumer
80
. Thickness of all the formulations was measured using a 
digital vernier 76 tandar. 
 
Friability: 
Friability is a measure of the resistance of the tablet to abrasion. Tablets are generally     
subjected to a 76 standardized level of abrasion for a given time and the friability is expressed as 
a % weight loss. The measure is useful to determine the ability of the tablet to withstand abrasion 
during handling, coating, packing and transport. The laboratory friability tester is known as the 
Roche friabilator. This device subjects the tablets to the combined effects of abrasion and shock 
by utilizing a plastic chamber that rotates at 25 rpm, dropping the tablets form a height of 6 
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inches with each revolution.
 
Twenty tablets were weighed accurately and placed in the friabilator 
and was operated for 100 revolutions or 4 minutes. The tablets were then de dusted and weighed. 
The weight loss of 0.5 to 1% is considered as acceptable limits for conventional uncoated tablets. 
The weight loss was calculated using the formula.
82 
 
                 
           
             
     
Disintegration Test: 
USP disintegration test specifies that one tablet is added to each of the six tubes in the 
USP disintegration apparatus. The apparatus is operated without disks, using simulated gastric 
fluid (pH 1.2) at 37
0
C for 2 hrs. The tablets are then removed and must show no evidence of 
disintegration, cracking or softening. Disks are then added and the apparatus is operated using 
simulated intestinal fluid (pH 7.4) at 37
0
C for a period of time limit specified in the monograph. 
The product passes the test if all tablets are disintegrated. 
 
Weight Variation Test:   
Twenty tablets were selected randomly and weighed individually. Calculate average 
weight and compare the individual tablet weight to the average. Not more than two of the 
individual weights deviate from the average weight by more than the percentage shown in and 
none deviate by more than twice the percentage.
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Percentage deviation = 
                                                  
                        
     
 
PERCENTAGE DEVIATION FOR WEIGHT VARIATION TEST 
Table No: 20 
S. No Average weight of tablet(mg)  Percentage  deviation 
1 80 mg or less ± 10.0 
2 More than  80 mg but less than 250 mg ± 7.5 
3 250 mg  or  more ± 5.0 
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4.5.7 IN-VITRO DISSOLUTION STUDIES: 
The release rate of Ibuprofen from tablets were determined using USP Dissolution 
Testing Apparatus 2 (paddle method).The test was performed using 900ml of 0.1N HCL at 
37
0
+0.5
0
C and 100 rpm for first 2 hrs. Then replaced with 7.4 pH phosphate buffer and 
continued for 24 hrs. A liquot volume of 5ml was withdrawn at regular intervals and replaced 
with fresh buffer diluted. The samples were replaced with fresh dissolution medium. The drug 
release is determined from the absorbance of the sample and standard. The results were tabulated 
in Table No: 34. 
Dissolution media Preparation: 
 
 Preparation of 0.1N HCl - 8.5 ml of concentrated HCl was added to 1000 ml of purified 
water and the pH is 1.2. 
 Preparation of pH 7.4 phosphate buffer- Dissolved 6.8g of potassium Dihydrogen 
phosphate in 1000 ml of purified water and adjusted the pH to 7.4 by using 0.1 N sodium 
hydroxide solution. 
 
TEST A 
Dissolution at Acid stage medium:  
 Dissolution Medium: 900 ml of  0.1 N HCL 
 Apparatus: USP Type II (Paddle) 
 Rotation: 100 rpm 
 Duration:  2 hours 
 Temperature: 37˚C ± 0.5˚C 
 
Standard Preparation  
Weigh accurately about 27.0 mg of Ibuprofen working standard in to 100ml volumetric 
flask, add 50ml of methanol, shake for 5 minutes and make up to volume with methanol. Pipette 
out 10ml of the solution in to 100ml volumetric flask and make up to volume with dissolution 
medium. Further dilute 5ml of this solution to 10ml volumetric flask and make up to volume 
with dissolution medium. 
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Test preparation:  
Withdraw 20ml of sample from each bowl and filter. Measure the absorbance of both 
standard and Test preparation at 222 nm using dissolution medium as blank and calculate the 
content of Ibuprofen per tablet. 
Calculation: 
 
                 
                   
 
                  
   
 
  
   
 
 
  
 
   
 
 
 
   
 
                  
           
      
 
TEST B                                             
Dissolution at Buffer stage medium:  
After filtering the dissolution medium for test A, drain the solution slowly without losing 
the tablet. Transfer the phosphate buffer medium to the bowl. 
 Dissolution Medium: 900 ml of  7.4 phosphate buffer 
 Apparatus: USP Type II (Paddle) 
 Rotation: 100rpm 
 Duration: 22 hrs. 
 Sampling time: 5, 8, 12, 16, 20, 24 hrs 
 Temperature: 37˚C ± 0.5˚C 
 
Standard preparation  
Weigh accurately about 27.0 mg of Ibuprofen working standard in to 100ml volumetric 
flask, add 50ml of methanol, shake for 5 minutes and make up to volume with methanol. Pipette 
out 10ml of the solution in to 100ml volumetric flask and make up to volume with dissolution 
medium. Further dilute 5ml of this solution to 10ml volumetric flask and make up to volume 
with dissolution medium. 
Test preparation 
Withdraw 10ml of test sample from the individual bowl at the end of 5
th
hr and filter. 
Measure the absorbance and calculate the content of Ibuprofen as indicated in test A. Withdraw 
10ml of test sample from the individual bowl at the end of 8
th
hr, 12
th
hr, 16
 th
hr, 20
 th
hr and 24
 th
hr 
and filter. Replace the bowl each time with buffer after withdrawal of the sample. Pipette out 1ml 
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of the filtrate and dilute to 20ml with the dissolution medium. Measure the absorbance of both 
standard and sample at 222 nm using dissolution medium as blank and calculate the content of 
Ibuprofen. 
 Calculation:  
                 
                   
 
                  
   
 
  
   
 
 
  
 
   
 
 
  
 
 
 
   
 
                  
           
      
 
4.5.8 ASSAY (By UV method) 
Preparation of standard solution 
 Weigh accurately 100.0 mg of Ibuprofen working standard in a clean, 100 ml volumetric 
flask and 10ml of Acetonitrile. Shake well to dissolve and make up the volume to 100ml with 
phosphate buffer. Mix well and dilute 5ml with of this solution to 50ml with Phosphate buffer. 
Further dilute 5ml of the resulting solution to 50ml with phosphate buffer.  
Preparation of sample solution 
Weigh accurately about 190 mg of crushed tablet powder in a clean, 200 ml volumetric 
flask and add add 10ml of acetonitrile. Shake well and make up the volume to 200 ml with 
Phosphate buffer. And dilute 5ml with of this solution to 50ml with Phosphate buffer. Further 
dilute 5ml of the resulting solution to 25ml with phosphate buffer 
Procedure 
 Measure the absorbance of both the standard and sample preparation at 222 nm using Phosphate 
buffer as blank. Assay was calculated from the following formula. 
Calculation: 
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4.5.9 STABILITY STUDIES 
84, 85, 86 
Stability of a formulation can be defined as the time from the date of manufacture of the 
formulation until its chemical or biological activity is not less than a pre-determined level of 
labeled potency and its physical characteristics have not changed appreciably or deleteriously. 
Formulation and the development of pharmaceutical products are not complete without proper 
stability analysis. It is carried out to assess the physical and chemical stability and safety use of 
the product. The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug products varies with the time under the influence of a variety of environmental 
factors such as temperature, humidity, and light enabling recommended for storage conditions 
and shelf life. The ICH guideline recommends the following storage conditions for stability 
studies:  
Table No: 21: Stability conditions according to ICH guidelines 
S. No. Study Storage Condition 
1. Long term 25°C±2°C / 60%RH±5%RH 
2. Intermediate 30°C±2°C / 65%RH±5%RH 
3. Accelerated 40°C±2°C / 75%RH±5%RH 
         
4.5.10 Accelerated stability studies 
 Generally the observation of the rate at which the product degrades under normal room 
temperature requires a long time. The International Conference of Harmonization (ICH) 
Guidelines titled “Stability testing for new drug substances and product” (Q1A) describes the 
stability test requirements for drug registration application in the European Union, and United 
States of America. The accelerated stability was carry out by ICH guidelines.  
 The formulation F6 was packed in high density polyethylene container and kept at 40
0
C ± 
2
0
C and 75% ± 5% RH. Samples were analyzed for drug content and in-vitro dissolution studies 
in the intervals of 1, 2, 3 months. The results of the stability studies are tabulated in              
Table No: 35, 36. 
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5. RESULTS AND DISCUSSION 
 
The present study was carried out to formulate colon targeted matrix tablet of Ibuprofen 
using direct compression method. In this method, the powder blend was subjected to various 
evaluation studies such as bulk density, tapped density, compressibility index and hausner’s ratio 
and was compressed into tablets. The compressed tablets were evaluated such as thickness, 
hardness, friability, weight variation, assay, in-vitro dissolution studies, and accelerated stability 
studies. The tablets are coated using Enteric coating polymers (Eudragit FS 30 D) to target the 
release of pH 7.4. The uncoated and coated tablets are evaluated for in-vitro dissolution studies 
and the tablets are packed in bluster pack and were subjected to accelerated stability studies. The 
results are presented in appropriate tables and figures. 
 
5.1 PREFORMULATION STUDIES: 
The following preformulation studies were performed on Ibuprofen and excipients. 
 
EVALUATION OF IBUPROFEN (API) 
5.1.1 PHYSICAL CHARACTERISTICS OF API 
Table No: 22 
S. No Tests Specification Results 
1 Colour White or off white powder 
White or off white 
powder 
2 Solubility 
Practically insoluble in water, freely soluble 
in acetone, methanol and in methlyene 
chloride. It dissolves in dilute solution of 
alkali hydroxide and carbonates 
Complies 
3 Melting point 75.0° -78.0°C 76.4°C 
4 
Moisture 
content 
NMT 0.5 w/w% 0.3%  w/w 
Discussion:  
The colour, solubility, melting point and moisture content of the API were evaluated. It 
was found to be within the range of the monograph. 
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5.1.2 ANGLE OF REPOSE OF IBUPROFEN 
Table No: 23 
 
 
 
 
 
 
Discussion:  
The angle of repose of API was found to be 38
0
.56΄± 0.69. Hence the drug belongs to fair 
flow and requires glidants to improve the flow property.  
 
5.1.2.1 BULK DENSITY AND TAPPED DENSITY OF IBUPROFEN 
Table No: 24 
S. No 
Raw 
material       
(API) 
Bulk density 
(g/ml) 
Average bulk 
density (g/ml) 
Tapped density 
(g/ml) 
Average 
tapped density 
(g/ml) 
1 Ibuprofen 0.459 
 
0.453 ± 0.01 
 
0.612 
 
0.614± 0.003 
 
2 Ibuprofen 0.452 0.614 
   3 Ibuprofen 0.448 0.618 
 
Discussion: The average bulk density and tapped density was found to be 0.453 ± 0.01 and 
0.614± 0.003 g/ml respectively. 
  
S. No Raw material  (API) Angle of repose (Degree) Average 
1 Ibuprofen 38
0.14΄  
38
0
.56΄± 0.69 
 
2 Ibuprofen 39
0.36΄ 
3 Ibuprofen 38
0.12΄ 
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5.1.2.2 POWDER COMPRESSIBILITY AND HAUSNER’S RATIO 
Compressibility Index and Hausner’s Ratio 
Table No: 25 
 
Discussion: 
Based on Compressibility index and Hausner’s ratio, it indicates the Ibuprofen (API) 
belongs to poor flow property. 
 
5.1.2.3 PARTICLE SIZE DISTRIBUTION 
   PARTICLE SIZE DISTRIBUTION OF IBUPROFEN  
Table No: 26 
Sieve 
no 
Empty 
weight of 
sieve 
Quantity 
retained (gm) 
Mass 
retained 
(gm) 
Cumulative 
mass retained 
(gm) 
Cumulative 
%  
retained 
Percentage 
passing % 
#20 367.8 368.55 0.75 0.75 4.34 95.66 
#30 417.65 417.85 0.2 0.95 5.5 94.5 
#40 358.05 365.65 7.6 8.55 49.56 50.44 
#60 343.45 343.65 0.2 8.75 50.72 49.28 
 #80 340.75 340.9 0.15 8.9 51.59 48.41 
 #100 332.5 332.85 0.35 9.25 53.62 46.38 
Base 540.45 548.45 8 17.25 100 0 
 
Discussion: 
 From the particle size analysis it was concluded that the particles size of the API was 
found to be moderately coarse powder.  
                                                 
Raw material  (API) Compressibility index (%) Hausner’s ratio 
Ibuprofen 26.22 1.35 
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 5.1.3 DRUG - EXCIPIENTS COMPATIBILITY STUDIES: 
          It was determined as per procedure given in material and method part. The following 
Table No: 27 illustrates,  
 DRUG - EXCIPIENTS COMPATIBILITY 
Table No: 27 
S. No Composition Initial After 15days After 30days Conclusion 
1 Ibuprofen White NCC NCC Complies 
2 Ibuprofen + Excipients White NCC NCC Complies 
 
 NCC- No Characteristic Change. 
Discussion: 
From the drug excipients compatibility study, it was observed that there was no 
characteristic change or interaction between drug and excipients. Thus it was concluded that the 
excipients selected for the formulation were compatible with Ibuprofen. 
 
IR SPECTRAL ANALYSIS: 
The FTIR studies of Ibuprofen and Ibuprofen with Excipients. The results are shown in Table 
No: 28, 29 Figure No: 9, 10. 
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FT-IR SPECTRA OF PURE IBUPROFEN  
Figure No: 9 
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FT-IR SPECTRAL VALUES OF PURE IBUPROFEN  
Table No: 28 
 
 
 
 
 
 
 
 
 
 
  
S. No Wave Number (cm
-1
) Functional Group 
1. 1720.0 C=O Stretching of carboxylic acid 
2. 1420.0 C=C Stretching of Benzene 
3. 1321.0 Methyl of alkane 
4. 1230.0 Methylene of Benzene ring 
5. 1068.0 C-O of carboxylic acid 
6. 935.5 CH2 bending vibration of alkane 
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FT-IR SPECTRA OF IBUPROFEN WITH EXCIPIENTS 
Figure No: 10 
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FT-IR SPECTRAL VALUES OF IBUPROFEN WITH EXCIPIENTS 
Table No: 29 
 
 
Discussion: 
Pure Ibuprofen spectra showed sharp characteristic peaks at 1720.0, 1420.0, 1321.0, 
1230.0, 1068.0, 935.5 cm
-1
. These peaks are also prominent in the FTIR spectra’s of the physical 
mixtures containing Ibuprofen and other excipients in the final formula. This indicates that there 
is no interaction between the drug and excipients from both Physical observation and FT-IR 
studies. 
 
 
 
  
S. No Wave Number (cm
-1
) Functional Group 
1. 1719.0 C=O Stretching of carboxylic acid 
2. 1420.0 C=C Stretching of Benzene 
3. 1380.0 Methyl of alkane 
4. 1230.0 Methylene of Benzene ring 
5. 1070.0 C-O of carboxylic acid 
6. 936.3 CH2 bending vibration of alkane 
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5.2 EVALUATION OF LUBRICATED POWDER BLEND 
Table No: 30 
Formulation 
Code 
Bulk density 
(gm/cm
3
) 
Tapped 
density 
(gm/cm
3
) 
Carr’s 
Index (%) 
Hausner’s 
ratio 
Angle of 
repose 
(degree) 
Moisture 
content                     
(%) 
F1 0.35±0.02 0.40 ± 0.01 11.73±0.79 1.12 ±0.15 29
058’±0.53 1.15 ± 0.05 
F2 0.31±0.03 0.35 ± 0.05 12.10±0.54 1.13 ±0.28 33
023’±0.35 1.28 ± 0.02 
F3 0.37 ± 0.01 0.42 ± 0.06 13.63±0.38 1.13 ±0.12 30
096’±0.19 1.42 ± 0.02 
F4 0.38 ± 0.07 0.40 ± 0.08 11.57±1.05 1.14± 0.85 31
026’±0.60 1.21 ± 0.06 
F5 0.35 ± 0.10 0.44 ± 0.06 12.60±0.86 1.12 ±0.74 29
035’±0.48 1.33 ± 0.03 
F6 0.41± 0.06 0.46± 0.01 12.98±0.65 1.13 ±0.24 31
0.05’±0.25 1.15 ± 0.02 
All values are expressed as mean ± standard deviation, n=3 
Discussion: 
The lubricated powder blends was evaluated for different parameters and the results are given in 
Table no: 30. 
 The bulk density and tapped density of all formulations were measured by using 
graduated measuring cylinder. The bulk density was found in the range of 0.31-
0.41gm/cm
3
. The tapped density was between 0.35-0.46 gm/cm
3
. Both are within the 
acceptable limits.  
 If the compressibility index of the powder is between 11 and 15, it shows good flow 
character, here all the formulations exist in the range between 11.73-13.63. It indicates 
that the granules showed good flow character. 
 The result showed that the Hausner ratio of all the formulations was between 1.12-1.14, if 
the Hausner ratio lies between 1.12-1.18, it shows good flow behavior of the granules or 
powder. The result indicates good flow property of the granules. 
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 If the angle of repose is within 350, it indicates good flow property of the granules. The 
result showed that the angle of repose of all the formulations was between 29
0
-33
0
.It 
proved that the flow properties of all formulations are good. 
 
5.3 EVALUATION OF FINISHED PRODUCT (UNCOATED) 
Table No: 31 
All values are expressed as mean ± standard deviation, n=3 
 
 
Discussion: 
The tablets are evaluated for different parameters are given in Table no: 31. 
 The thickness of the tablets was in the range of 3.4 to 5.9 mm. This is due to the upper 
and lower punch adjustments during compression process.         
 The prepared tablets in all the trials possessed good mechanical strength with sufficient 
hardness in the range of 12.6 to 5.2 kg/cm
2
.  
Parameters F1 F2 F3 F4 F5 F6 
Average weight 
(mg) 
450±1.18 450±0.89 450±2.00 450±0.61 450±2.68 450±0.21 
Thickness (mm) 3.4± 0.16 4.2±0.09 4.7± 0.14 5.9± 0.12 5.7±0.01 5.9 ± 0.16 
Hardness (kg/cm
2
) 
12.6 
(± 0.15) 
9.4 
(± 0.22) 
6.2 
( ± 0.30) 
5.2 
( ± 0.32) 
6.0 
( ± 0.30) 
5.8 
( ± 0.11) 
Friability     (%) 0.36 0.41 0.39 0.31 0.35 0.33 
Disintegration 
time (min) 
- 24’46’’ 17’42’’ 14’45’’ 8’42’’ 7’18’’ 
Assay (%) 99.34 99.2 98.51 99.85 99.53 100.21 
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 The friability of the tablets was found to be within 1%. All the above trail formulations 
have passed the friability test. 
 The average weight of all the formulations was found to be 450mg. It is within the 
permissible range. 
 The percentage of drug content was found among different batches of the tablets and 
ranged from 98.5 to 100.21 which were within the acceptable limits. 
 
5.4 EVALUATION  PARAMETERS OF IBUPROFEN ENTERIC COATED TABLETS 
Table No: 32  
Trial 
Thickness 
(mm) 
Weight variation        
(mg) 
Disintegration 
time(min) 
Assay (%) 
Drug release 
(%) 
F6 6.0 ± 0.02 477±0.21 218’63’’ ±1.98 99.92 ± 0.08    98.51 
All values are expressed as mean ± standard deviation, n=3 
 
Discussion: 
Ibuprofen tablet of the above trial (F6) was satisfied of all the parameters. It was coated 
by using enteric coating method. The coated tablets were evaluated for the following parameters 
including thickness, disintegration test, weight variation, assay and in-vitro studies.  
 
5.5 COMPARATIVE DATAS OF UNCOATED AND ENTERIC COATED IBUPROFEN 
TABLETS 
Table No: 33 
Trial Thickness (mm) 
Weight 
variation (mg) 
Assay   (%) 
Drug release 
(%) 
F6 Un coated 5.9 ± 0.16 451±5 100.21±0.12 99.69 at 12 hrs 
F6 
Enteric coated 
6.0±0.02 477±5 99.92 ± 0.08 98.51 at 24 hrs 
 All values are expressed as mean ± standard deviation, n=3 
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Discussion: 
Ibuprofen Enteric coated tablets were compared with the same trial of uncoated Ibuprofen 
tablets. The thickness of Enteric coated tablets was found to be more than uncoated tablets. 
Weight variation was increased in Enteric coated tablets than the uncoated tablets. This is due to 
the coating of core tablet.  
         
5.6 IN-VITRO DISSOLUTION PROFILE OF ENTERIC COATED TABLETS 
Table No: 34 
 
Dissolution 
Media 
Sampling 
time 
 
Cumulative% drug release in different trials 
F3 F4 F5 F6 
Simulated gastric fluid 
(0.1 HCL) 
2 Hrs 1.07 1.60 1.83 2.00 
Simulated          
Intestinal Fluid 
(7.4pH Phosphate 
buffer ) 
5  Hrs 7.43±0.32 8.804±0.13 10.09±0.78 11.58±0.13 
8 Hrs 10.09±0.78 12.74±0.43 16.76±0.13 20.72±0.43 
12 Hrs 26.97±0.52 36.82±1.35 49.76±0.57 53.80±0.78 
16 Hrs 45.18±0.95 61.24±0.52 72.21±0.95 81.51±0.57 
20 Hrs 61.24±0.57 72.19±0.43 84.31±0.57 90.71±0.95 
24 Hrs 78.22±0.78 82.43±0.57 92.65±0.95 98.51±0.78 
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Figure No: 11 
Graphical representation of in-vitro drug release 
 
 
 
Discussion: 
F1:  The method used in this trial is direct compression. The concentration of Eudragit S 100 
used was 80 mg/unit, Ethyl cellulose concentration was 60mg/unit. Lactose DCL 21 was 
50mg/unit. And the concentration of Talc and magnesium stearate used was 5mg/unit. The 
hardness of the tablet were crossed the specification limit. 
F2: Same as procedure of F1. But in this formulation the concentration of Eudragit S100 and 
Ethyl cellulose was decreased to 60 mg/unit and 55mg/unit. And diluent concentration increased 
to 75mg/unit. The hardness of this formulation were better than the above formulation but the 
time required to disintegrate tablets were crossed the specification limit. 
F3: The hardness were achieved. But the time required to disintegrate tablets were crossed the 
specification limit. In this formulation the concentration of Eudragit S100 and Ethyl cellulose 
was decreased to 50 mg/unit and 40 mg/unit to reduce the hardness of the tablets. And the diluent 
concentration increased to 100mg/unit. This formulation was selected for coating. And the 
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tablets were subjected to in-vitro dissolution study. The release was found to be 78.22±0.78 at 24 
hrs. 
F4: In trial 4 the concentration of Eudragit S100 and Ethyl cellulose was further decreased to 
35mg/unit and 25mg/unit and increased the Lactose DCL21 concentration to 130mg/unit. The 
disintegration time of tablet was better than the above formulations but crossed the limits. The 
tablets were subjected to in-vitro dissolution study. 
F5: The concentration of Eudragit S100 and Ethyl cellulose was further decreased to 20mg/unit 
and 15mg/unit and increased the Lactose DCL21 concentration to 154mg/unit. The concentration 
of Magnesium stearate was increased to 6mg/unit to improve the lubrication of granules. The 
disintegration time of tablet was found to be within the limit. The triethyl citrate was used in the 
enteric coating part, to give better flexibility to the polymer. The tablets are subjected to in-vitro 
dissolution study. The percentages of drug release were found to be 92.65±0.95 at 24 hrs. It was 
better than the earlier trials. 
F6: The concentration of Eudragit S 100 and Ethyl cellulose was further decreased to 14mg/unit 
and 10mg/unit and increased the Lactose DCL21 concentration to 165mg/unit. The tablets of this 
trial are subjected to in-vitro dissolution study. The percentage of drug release showed 
98.51±0.78 at 24 hrs. This trial was taken as confirmatory trial and subjected as stability 
studies.  
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5.7 STABILITY STUDIES 
5.7.1 PHYSICAL PARAMETERS 
Stability studies for post compression parameters of (F-6) enteric coated tablets 
Table No: 35 
Post  compression 
Parameters 
Storage condition: 40
0
C± 2
0
C /75±5%RH 
Initial 1
st
 month 2
nd
 month 3
rd
 month 
Description 
White coloured 
Enteric coated 
tablet 
White coloured 
Enteric coated 
tablet 
White coloured 
Enteric coated 
tablet 
White coloured 
Enteric coated 
tablet 
Average weight       
(mg) 
477±0.21 477.38 ± 0.003 477.52 ± 0.006 477.67 ± 0.04 
Disintegration time 
(minutes) 
219’63’’±0.03 219’13’’±0.08 220’ 38’’±0.08 221’ 7’’ ±0.05 
 *All the values are expressed as mean’s, n=3. 
 
Discussion:   
The F-6 formulation of enteric coated tablets was carried out for the stability study. It was 
kept at 40
0
C± 2
0
C /75±5%RH.  It revealed that there were no significant changes in color but 
slight increase in average weight and disintegration time. The sample was tested at one month 
interval. 
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5.7.2 IN-VITRO DRUG RELEASE AND ASSAY 
Table No: 36 
Formulation 
Time in 
hrs 
Storage condition 40
0
C±2
0
C /75±5%RH 
In-vitro drug release (%) Assay (%) 
Initial 1 month 2 month 3 month Initial After Stability 
F6 24 98.51 98.31 97.42 97.28 100.21 100.1 
 
Discussion: 
The F6 formulation of enteric coated tablets was carried out for the stability study, it was 
kept in 40
0
C± 2
0
C /75±5% RH for the period of three months. Percentage of drug release and 
assay was determined. The data’s does not showed much variation during stability studies. The 
results revealed that the product was stable.  
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6.  SUMMARY AND CONCLUSION 
The present work involves the formulation of colon targeted matrix tablet of Ibuprofen by 
using direct compression method. Literatures regarding, Ibuprofen tablet dosage form 
preparation, excipients selection, manufacturing method, etc., has been collected and reviewed. 
In this work, selection of excipients was done based on a literature review. Excipients 
include Eudragit S100, Ethyl cellulose, Lactose, Talc, Magnesium stearate. Quantities of the 
excipients were selected by performing FT-IR method which is an IHS of Fourrts India 
Laboratory. 
Preformulation studies have also been performed to study the nature of API and 
compatibility of API with excipients by physical observation and FT-IR studies. The result 
showed that API was compatible with all the excipients selected. 
The tablets were formulated by direct compression method using the selected excipient 
quantities. The formulated tablets were tested for both pre-compression parameters and post 
compression parameters as per requirements of standards. Pre-compression parameters such as 
bulk density, tapped density, compressibility index, Hausner’s ratio and compressibility index. 
The results obtained indicate that it has good flow property for direct compression. 
The formulated Ibuprofen matrix tablets were coated with enteric polymer Eudragit FS 
30D by pan coating method. The prepared tablets were evaluated for weight variation, hardness, 
thickness, friability, drug content, disintegration time and in-vitro dissolution studies. All these 
parameters were found to be within the standard limits. 
Comparative studies of coated Ibuprofen tablets and uncoated Ibuprofen tablets are 
evaluated for the hardness, thickness, in-vitro dissolution studies and disintegration time. 
Out of six formulations, the formulation F6 showed 98.51% drug release at 24 hrs. Since 
it provide greater protection to the core under acidic condition while at the same time show the 
fastest drug release under intestinal pH. So the formulation F6 was considered as the 
confirmatory trial and it was subjected for stability studies up to three months of accelerated 
stability 40
0
C ± 2C
0
, 75 % ± 5 % RH and found to be within limits.  
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CONCLUSION 
Preformulation studies were performed to study the nature of API and compatibility of 
API with excipients by physical observation and FT-IR studies. The results showed that there 
was no interaction between API and all the excipients selected.   
The Ibuprofen matrix tablets were successfully formulated by direct compression method 
using the selected excipient quantities. The formulated tablets were evaluated for both            
pre-compression and post-compression parameters as per requirements of standards. And the 
results were complied with the pharmacopoeia specification. The formulated Ibuprofen matrix 
tablets were coated with enteric polymer Eudragit FS 30D by pan coating method. 
From among the entire batches, formulation F6 showed 98.51% drug release at 24 hrs. 
Since it provide greater protection to the core under acidic condition while at the same time show 
the fastest drug release under intestinal pH. So the trial F6 was considered as best formulation. 
From the results obtained, it can be concluded that formulation F6 containing enteric coated 
matrix tablet of Ibuprofen would be a promising formulation to achieve the purpose which treat 
inflammatory bowel diseases (ulcerative colitis) without any gastric irritation or ulcers, which is 
useful for patients having pre history of ulcerative colitis. 
  
 
Chapter 7 
Future study 
 
 
 
Chapter 7                                                                                                                      Future study 
 
S.B.C.P                                             Department of Pharmaceutics Page 100 
 
 
7. FUTURE STUDY 
 
The finding of the present study has initiated the company to go in for scale up trial. 
Based on the reproducible results produced from batch to batch the company will decide to 
launch the product in the future. 
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